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1. State of the art 
1.1 Introduction: Serotonin, the happiness hormone 
Serotonin, also known as 5-hydroxytryptamine (5-HT), is a molecule well known 
for its positive influence on the mood and its protective properties against the onset 
of various mental and physical disorders (1). Therefore it is popularly known as the 
“happiness” or the “happy” hormone.  
 5-HT is a monoamine synthesized in the serotonergic neurons of the central 
nervous system and the enterochromaffin cells of the gastrointestinal tract (2-4). It 
binds and activates G-protein coupled 5-HT receptors. These are diverse, and 
ubiquitously expressed in the human organism, and possess a wide range of 
functions (2, 5, 6). This is not surprising since 5-HT is probably one of the oldest 
neurotransmitters/hormones in the evolution of life (6). In the last 20 years, seven 
families of 5-HT receptors have been identified and various subtypes have been 
described. The increasing number of 5-HT receptors and the lack of suitable selective 
agents, have made it difficult to unravel the roles of the 5-HT receptor 
subpopulations(5).  
Since 5-HT receptors are widely expressed in the central nervous system (CNS), 
5-HT takes part in plentiful brain functions (7, 8). Until now 5-HT has established its 
role in significant psychiatric disorders, such as depression, anxiety, obsessive-
compulsive disorder, eating disorders, nausea and centrally-induced emesis, 
dependence, cognitive disorders and migraine (2, 5, 7, 9). 
[2] 
 
In the periphery 5-HT is involved in numerous physiological functions.  These 
include hypoglycemic effects, stimulation of lipid accumulation, gastrointestinal 
motility, intestinal secretion, inflammation, liver regeneration, uterine contraction, 
pulmonary artery remodeling, vascular tone and permeability, platelet aggregation, 
and chronotropic and inotropic myocardial effects (2, 7, 10-14). 
The understanding of the 5-HT related physiological functions are of clinical 
importance, especially with regard to the treatment of depressive disorders, irritable 
bowel disease and chemotherapy–induced nausea with medications that inhibit 5-
HT re-uptake and 5-HT receptors (7). Further clinical importance relates to the 
association of peripheral 5-HT with autoimmune diseases, liver diseases, and 
asthma, conditions which 5-HT-modifying medication might target in the future (15-
20). 
1.2 Biosynthesis and degradation of 5-HT 
5-HT is a common monoamine in the human body. 5-HT is produced by 
enterochromaffin cells of the gastrointestinal tract and part of it is secreted into the 
blood. Then, 5-HT is taken up via the serotonin transporter (SERT) and stored in 
platelets and pulmonary neuroepithelial bodies. 5-HT is also produced by the 
serotonergic neurons, which almost exclusively originate in the raphe nuclei located 
in the midline of the brainstem (3, 4, 7).  
5-HT is synthesized by initial hydroxylation of the essential amino acid L-
tryptophan. This first step is also the rate-limiting step in 5-HT biosynthesis. L-
tryptophan is transported through the blood-brain barrier by the neutral amino acids 
transmitter, on which it competes with other amino acids such as phenylalanine, 
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leucine and methionine. Tryptophan hydroxylase catalyzes the conversion of 
tryptophan into 5-hydroxytryptophan. Two isoforms of tryptophan hydroxylase can 
be distinguished, one expressed in the brain in serotonergic neurons and the other 
one in the periphery (2, 5, 21). 5-hydroxytryptophan is then further converted to 5-
hydroxytryptamin (5-HT) by the aromatic L-amino acid decarboxylase (Figure 1.1) (2, 
5).  
Figure 1.1: Biosynthesis and degradation of serotonin. 
 
5-HT is metabolized by the monoaminoxidase enzyme (MAO) into 5-
hydroxyindole acetic acid (5-HIAA) by oxidative deamination. Two types of MAO, 
MAO-A and MAO-B exist in neurons, but only MAO-B in platelets. Circulatory 5-HT is 
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metabolized mainly in the liver. Also the endothelium of pulmonary capillaries is able 
to degrade 5-HT. Brain 5-HIAA is actively transported into the periphery and secreted 
along with the 5-HIAA of non-CNS origin in urine (2). 
Notably 5-HT is not able to pass the blood-brain barrier; thus the 5-HT systems of 
the CNS and the periphery are considered to be mutually independent (11). 
1.3 5-HT transporter (SERT) and 5-HT receptors 
The 5-HT transporter (serotonin transporter; SERT) is a monoamine transporter 
consisting of 12 transmembrane regions (74 kDa). SERT demonstrates high affinity 
for the uptake of 5-HT (3, 22-24).  SERT has been located on neuronal cells and takes 
part in regulating the strength and duration of the serotonergic signal transmission. 
SERT is also expressed in peripheral cells on the plasma membrane of platelets, 
lymphoblasts, monocytes, enterochromaffin cells, endothelial cells and placental 
syncytiotrophoblasts (22). Peripheral and neuronal SERTs are considered largely 
identical in structural and functional properties (23, 25). 
5-HT interacts with a diversity of receptors which are mainly G-protein-coupled 
receptors (GPCRs). The 5-HT receptors are currently classified into 7 different 
families, some of them containing  further subtypes (6). An overview of the 5-HT 
receptor classification, the coupling to G-proteins or ion channels, and the main 
signaling mechanisms is shown in Table 1. 
 
 
 
 
 
[5] 
 
 
Table 1: 5-HT receptor families 
5-
HTreceptor 
family 
Subtypes Coupling Signaling mechanism 
5-HT1 
5-HT1A, 5-HT1B, 5-
HT1D, 5-HT1E, 5-HT1F 
Gi/0-protein 
coupled 
Decreasing cellular cAMP levels 
via inhibition of adenylate 
cyclase activity 
5-HT2 
5-HT2A, 5-HT2B, 5-
HT2c 
Gq/11-protein 
coupled 
Increases cellular levels of IP3 
and DAG via activation of 
phospholipase C 
5-HT3 5-HT3A, 5-HT3B 
Ligand-gated 
ion channel 
Membrane depolarization via 
Na+- and Ca++-influx, K+ efflux 
5-HT4 
5-HT4A-5-HT4N  
(at least 9 
variants) 
Gs-protein 
coupled 
Increasing cellular cAMP levels 
via stimulation of adenylate 
cyclase activity 
5-HT5 5-HT5A, 5-HT5B  
Gi/0-protein 
coupled 
Decreasing cellular cAMP levels 
via inhibition of adenylate 
cyclase activity 
5-HT6 5-HT6 
Gs-protein 
coupled 
Increasing cellular cAMP levels 
via stimulation of adenylate 
cyclase activity 
5-HT7 
5-HT7A, 5-HT7B, 5-
HT7C, 5-HT7D 
Gs-protein 
coupled 
Increasing cellular cAMP levels 
via stimulation of adenylate 
cyclase activity 
 
Before the current knowledge on the role of 5-HT in platelets is presented, a 
short insight into the platelet morphology and function will be provided. 
1.4 Platelets and platelet function 
1.4.1 Platelet origin and morphology 
Platelets originate from a type of large nucleated hematopoietic stem cells, the 
megakaryoblast, within the bone marrow. The mature megakaryocytes create long 
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cytoplasmic processes, designated as proplatelets, through junctions in the lining of 
blood sinuses. Platelets are released from the tips of these proplatelets into the 
circulation. Each megakaryocyte can release up to 1000-3000 platelets. Many 
aspects of platelet formation mechanisms by megakaryocytes are still poorly 
understood though (26, 27). 
Platelets are small, 2-3 µm in diameter, anucleate disc-shaped cells. Normally 
about two thirds of platelets are present in the circulating blood at concentrations of 
150.000-400.000 platelets/µl; one third of platelets is reversibly sequestered in the 
spleen. The circulating platelet population is replaced every 7-10 days. The site of 
platelet degradation is the reticulo-endothelial system of the liver and spleen (27, 
28). 
Platelets have a complex morphology consisting of distinct membrane systems, 
and cytoskeletal structures, and containing different granules and organelles.  
The three distinct membrane systems are the following: 
- The plasma membrane contains specific GPCRs and is densely packed with 
glycoprotein receptors which regulate platelet activation, adhesion and 
aggregation.  (27-29). 
- The open canalicular system (OCS) is connected to the cell surface and 
although its role has not been entirely defined, it possibly serves as (a) a 
mechanism for entry of external elements into the platelets, (b) a mechanism 
for release of the dense and α-granule constituents into the extracellular 
space, (c) a depository of surface glycoproteins and (d) an internal membrane 
reservoir for the formation of filopodia and spreading of platelets upon 
adhesion and activation (27). 
[7] 
 
- The dense tubular system is a closed channel network of residual 
endoplasmic reticulum, in which ionized calcium (Ca++) is stored and released 
upon platelet activation (27, 30). 
The resting platelet cytoskeleton maintains the integrity and shape of the 
platelet, even under high shear forces in the circulation, and consists of: 
- The spectrin-based membrane skeleton, which supports the plasma 
membrane and the OCS (31). 
-  The actin cytoskeleton. Forty percent of actin is organized as F-actin into 
filaments, whilst the rest (G-actin) is stored in the cytoplasm and forms 
filaments upon platelet activation. Actin filaments bind with the glycoprotein 
Ib. They add to the stability of the platelet shape and regulate the topological 
distribution of surface glycoproteins in activated platelets (27, 28, 32). 
- The marginal band of microtubules consisting of α- and β- tubulin, supports 
the discoid shape of resting platelets, and depolymerizes rapidly upon 
platelet activation (27). 
The platelets contain also the following granules and organelles: 
- The α-granules contain a diversity of biologically active proteins, which are 
involved in platelet adhesion and aggregation (vWf, thrombospondin), 
chemotaxis of other blood cells (β-TG, PF4), angiogenesis at sites of vascular 
injury (VEGF, endostatin), smooth muscle cell proliferation and migration 
(PDGF), inflammation (P-selectin, IL-1, CD40-ligand) and coagulation (factor 
V, fibrinogen, PAI-1) . Their diameter is typically 200-500 nm and upon 
platelet activation they merge with the plasma membrane or the OCS (27, 
28). 
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- The dense granules are a little smaller in diameter (200 nm), and contain ATP, 
ADP, Ca++, polymers of inorganic phosphate and, the main molecule of our 
study, 5-HT. They have also been reported to contain epinephrine. The 
secretion of dense granule constituents serves mainly as a feedback for 
platelet activation (27, 33-35). 
- The lysosomes release degrading enzymes which may play a role in the 
restructuring of vessel walls after injury (27, 28). 
- The peroxisomes contain the enzyme catalase (27). 
- The mitochondria supply the platelet with energy during its 7-10 days 
lifespan (27). 
1.4.2 Platelet adhesion 
Platelets circulate in blood in a resting state and do not adhere to undamaged 
vessel walls (36). They are circulating monitors of the vessel integrity and at sites of 
vascular injury, they adhere to the exposed subendothelial extracellular matrix (28, 
36, 37). The adhesion of the still resting platelets is known as primary adhesion, in 
contrast to the adhesion of already activated platelets, which is known as secondary 
platelet adhesion (28). Platelet adhesion occurs under venous and arterial flow 
conditions, with their lower and higher shear stress rates, respectively (36). At low 
shear rates (<500 s-1), such as in veins and larger arteries, platelets adhere primarily 
to collagen, fibronectin and laminin. At higher shear rates (>1000 s-1) as in smaller or 
stenotic arteries, the platelet surface glycoprotein Ibα (GPIbα), part of the 
glycoprotein Ib-V-IX complex, has a crucial role. Its high affinity interaction with von 
Willebrand factor (vWF), which binds to and is immobilized on collagen of the 
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subendothelial matrix, slows down the fast flowing platelets, enabling primary 
platelet adhesion (28, 36, 37). The reduced platelet velocity allows interactions with 
further platelet receptors, thereby stabilizing platelet adhesion. Such interactions 
occur between the platelet integrin α2β1 and glycoprotein VI (GPVI) with collagen 
and between the integrin αIIbβ3 (glycoprotein IIbIIIa ; GPIIbIIIa) with fibrinogen (38) 
(Table 2). Platelets can also adhere to vWf via αIIbβ3, to laminin via α6β1, to 
ﬁbronectin via α5β1 and αIIbβ3, to thrombospondin via GPIba, to collagen via GPIV, 
and to vitronectin via αvβ3, interactions that perhaps regulate platelet adhesion to 
different compositions of extracellular matrix. Yet, the contribution of each of these 
interactions remains to be investigated (36, 37) (Table 2). Subsequently, platelets 
undergo activation leading to shape change, secretion, and spreading on the surface 
of the extracellular matrix, a process regulated mainly by the integrin αIIbβ3. This 
allows more extensive interaction of the platelet receptors with the extracellular 
matrix and comprises a mechanism to better withstand the shear forces of the 
flowing blood (28, 37). 
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Table 2:  Main integrins and glycoproteins, their ligands and copies per platelet. 
Name Ligand Copies per platelet References 
αIIbβ3 
fibrinogen (vWf, 
fibronectin) 
 ̴60.000-100.000  (part of this 
population is stored in internal 
pools and is externalized upon 
platelet activation) 
Gawaz(28), 
Michelson(39) 
α2β1 collagen (vWf) ̴ 1000-4000 
Gawaz(28),  
Broos et al.(36) 
α5β1 fibronectin  ̴1000 Gawaz(28) 
α6β1 laminin ̴ 1000 Gawaz(28) 
αvβ3 vitronectin ̴ 100 Gawaz(28) 
GP Ib/V/IX 
complex 
vWf ̴ 25.000 Gawaz(28) 
GP IV collagen ̴ 15.000-25.000 Gawaz(28) 
GP Iba thrombospondin ̴ 25.000 Gawaz(28) 
GP VI collagen  ̴1000-9000 
Burkhardt et al. 
(40),  
Nieswandt et 
al.(41) 
 
1.4.3 Platelet activation and aggregation  
After platelet deceleration by the GPIb-vWF- interaction, the binding of GPVI and 
integrin α2β1 to collagen triggers specific signaling pathways leading to platelet 
activation (42-44). The mild bleeding diathesis of patients with GPVI or integrin α2β1 
deficiency might indicate that these two activation pathways are mutually 
independent, rather than the dependence of  integrin α2β1 activation on GPVI, 
although this is a matter of controversy (36). GPVI is more efficient in signaling than 
the integrin α2β1. Signaling includes the activation of Src-family and Syk-tyrosine 
kinases and leads to an explosion of activation events. These include the 
phospholipase Cγ2 (PLCγ2)-mediated increase of IP3 (inositol 1,4,5-trisphosphate ) 
and DAG (diacylglycerol) leading to cytosolic Ca++ increase and protein kinase C 
activation respectively (36). 
[11] 
 
Phospholipase A2 activated by increased cytosolic Ca
++ and protein kinase C 
catalyzes the liberation of arachidonic acid (AA) from membrane phospholipids. AA 
in turn is converted to thromboxane A2 (TxA2), a potent platelet activator. TxA2 is 
released from platelets to generate feedback amplification of platelet activation and 
also to provoke smooth muscle cell contraction. The binding of TxA2 to its Gq-
coupled platelet surface receptor activates PLCβ2, whose pathway is similar to 
PLCγ2. Alternatively, the platelet thromboxane receptor couples to the G13-protein, 
whose activation stimulates the Rho/ Rho-kinase pathway mediating further platelet 
activation (28, 36). 
Another crucial step is the preparation of platelets to form bridges with other 
platelets (i.e. platelet aggregation). The integrin responsible for this function, αIIbβ3, 
has a low affinity for its ligands (fibrinogen and vWF) on resting platelets. The 
cytosolic increases of Ca++ and DAG mediate a conformational change of the integrin 
αIIbβ3 enabling it to bind its ligands (mainly fibrinogen). A molecule of fibrinogen can 
then bind with two αIIbβ3 receptors on two activated platelets and forms a bridge 
between them (36). 
1.4.4 Secretion of platelet granule contents and amplification of platelet 
activation 
The rise of cytosolic Ca++ and activation of protein kinase C (PKC) in stimulated 
platelets lead to fusion of the granules with the cytoplasmic membrane. Lipid 
components, soluble N-ethylmaleimide sensitive attachment protein receptors 
(SNARE) proteins, that form a fusion machinery, and chaperone proteins, which 
[12] 
 
modulate the SNARE-proteins, have been shown to take part in the secretion 
process (45). 
As mentioned above, α-granules contain a diversity of biologically active 
proteins, which serve to foster platelet adhesion, platelet aggregation, chemotaxis 
and angiogenesis at sites of vascular injury. Fibrinogen and vWF released from α-
granules reinforce platelet activation, platelet recruitment and platelet-platelet 
interactions (36).  The expression of the α-granule proteins integrin αIIbβ3  and P-
selectin on the platelet surface also supports platelet aggregation and adhesion (28). 
Furthermore, the coagulation factors V, XI and XIII and prothrombin are also 
released and enhance thrombus stabilization (36). Thrombin, in particular, which is 
generated from prothrombin in the vicinity of activated platelets, interacts with the 
Gq-coupled PAR-1 and PAR-4 receptors stimulating PLCβ, and recruits circulating 
non-activated platelets to the platelet thrombus (46).  
Notably recent studies indicate that the population of α-granules is 
heterogeneous. For example the vascular endothelial growth factor (VEGF; 
angiogenesis stimulator) and endostatin (an angiogenesis inhibitor) have been found 
to be segregated into separate and distinct α-granules and to be differentially 
secreted: VEGF in PAR-1 and endostatin in PAR-4activated platelets, respectively (47, 
48). 
The dense granules play a major role in amplification of the platelet response. 
The released ADP binds to the Gq-coupled receptor P2Y1 activating the PLCβ-
dependent signaling pathway, and to the Gi-coupled P2Y12 receptor suppressing 
intracellular levels of cAMP.  The second messenger cAMP is a well-known inhibitor 
of platelet activation (36, 46, 49). Secreted ATP binds to the P2X1 channel provoking 
[13] 
 
influx of extracellular Ca++ and resulting in potentiation of platelet shape change and 
granule secretion (36, 50). Epinephrine has also been found to be released from 
dense granules and to stimulate the α2-adrenergic receptor on the platelet surface. 
This receptor is like the P2Y12 receptor Gi-coupled, and potentiates platelet 
activation (34, 51). 5-HT secreted from dense granules can be taken back up by the 
5-HT transporter (SERT) of platelets or it interacts with the 5-HT2A receptor on the 
platelet surface (6, 23, 52). The role of 5-HT in platelet activation will be discussed 
below. 
Lysosomes secrete degrading enzymes that may take part in clot remodeling and 
further platelet activation (53). The lysosomal enzymes loosen the subendothelial 
structure and play a pathophysiological role in restructuring the vessel wall during 
atherosclerosis (28). 
An overview of the main platelet G-protein coupled receptors and their ligands is 
shown in Table 3. 
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1.4.5 Platelet aggregation 
Platelet aggregation is defined as the process of co-adhesion between two 
platelets; the platelet aggregate is the final step of primary hemostasis and stops 
blood loss from damaged vessels (28). 
At lower shear rates (<1000 s-1) the activation of the integrin αIIbβ3 (fibrinogen 
receptor) by platelet agonists and the successive bridging of two αIIbβ3 receptors 
with one fibrinogen molecule predominates the aggregation process (36). At higher 
shear rates (1000 – 10000 s-1) non-activated discoid platelets form transient 
adhesive contacts with other adherent platelets through interactions of the 
glycoprotein Ib with vWF, and of integrin αIIbβ3 with fibrinogen. This initial step of 
aggregation is further supported by the narrow space between aggregating platelets 
Table 3:  Main platelet G-protein coupled receptors (GPRCs), their ligands and copies per platelet. 
Name Coupling Ligand Copies per platelet Reference(s) 
Thromboxane 
receptor 
Gq, G12/13 Thromboxane  ̴1000-2000 Hechler et al. (54) 
PAR-1 Gq, Gi, G12/13 Thrombin ̴ 500-2000 Hechler et al. (54) 
PAR-4 Gq, G12/13 Thrombin unknown 
Michelson (39), 
Molino et al. (55) 
P2Y1 receptor Gq ADP  ̴ 150 Purvis et al. (56) 
P2Y12 receptor Gi ADP  ̴400 
Ohlmann etal. 
(57) 
PAF receptor Gi, Gq PAF ̴ 300 Michelson (39) 
α2-adrenergic 
receptor 
Gi Epinephrine ̴ 300 
Pozgajova et al. 
(58) 
β2-adrenergic 
receptor 
Gs Epinephrine unknown  
5-HT2A receptor Gq 5-HT unknown 
Khait et al.(59), 
Spiegset et al. 
(60),  Coccaro et 
al. (61) 
5-HT4 receptor Gs 5-HT unknown  
IP receptor Gs PGI2 unknown Colman (62) 
EP3 receptors Gi PGE2 unknown Michelson (39) 
EP2 and EP4 
receptors 
Gs PGE2 unknown Michelson (39) 
[15] 
 
which facilitates the accumulation of soluble platelet agonists such as ADP, TxA2, 
thrombin (36). Platelet inside-out signaling leads to integrin αIIbβ3 activation, and to 
its binding of fibrinogen, but also of vWF and fibronectin, which results in the 
formation of stable platelet aggregates. Besides integrin αIIbβ3, other surface 
molecules have been recently implicated in thrombus stability (36). Finally, the 
platelet thrombus is consolidated by a network of fibrin during the processes of 
secondary hemostasis (36, 37).  At very high shear (>10.000 s-1) platelets aggregate 
almost exclusively due to vWF-GPIb interactions (36).  
1.5 Uptake, storage and release of 5-HT by platelets  
The concentration of 5-HT in platelet-poor or platelet-depleted plasma is very 
low: 179 nM and 0.6 nM, respectively (63, 64).  Circulating 5-HT is taken up by SERT 
into the platelet cytoplasm (65, 66). Cytosolic 5-HT is then transported into the 
dense granules by the vesicular monoamine transporter (VMAT) (67, 68), where it is 
stored along with ATP, ADP, high levels of Ca++ and inorganic phosphate polymers 
(33). 5-HT in the dense granules is not freely diffusible and forms large molecular 
aggregates with ATP, which are stabilized by the divalent cations found in the same 
granules (69). The dense granule concentration of 5-HT is very high, and varies in 
different studies between 65 mM and 0.5 M (33, 69). The mass of 5-HT has been 
approximately estimated as 589 ng  (3.34  nmol) 5-HT per 109 platelets (15). Upon 
exposure to subendothelial matrix and upon stimulation by agonists, including 
thrombin, thrombin receptor activating peptide (TRAP), thromboxane analogues and 
ADP, platelets undergo degranulation, which leads to 5-HT secretion into the 
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extracellular space (33, 70). 5-HT can then interact with platelet 5-HT receptors or it 
is taken up again by the platelet 5-HT transporters.  
Few studies have studied the 5-HT content in other blood components. Until 
now, 5-HT has also been found in erythrocytes, lymphocytes, monocytes and mast 
cells. The existence of 5-HT in granulocytes is still controversial (71-75).  
1.6 The platelet 5-HT transporter (SERT) and selective serotonin 
reuptake inhibitors (SSRI) 
1.6.1 The platelet 5-HT transporter (SERT) 
The 5-HT transporter (SERT) is a Na+/Cl--dependent solute carrier transporter 
(SLC6 family) consisting of 12 transmembranous regions (23, 76). The uptake of 
extracellular 5-HT takes part in two steps. In the first one, an extracellular 5-HT 
molecule binds with SERT and is transported into the cell along with an ion of Na+. In 
the second step K+ is countertransported across the membrane to the outside of the 
cell (23).  
SERT is a membrane-skeleton-associated protein, and its regulation in platelets is 
complex. Studies of washed platelets have shown that extracellular 5-HT 
concentrations as low as 1 nM increase SERT expression on the plasma membrane 
and 5-HT uptake; whereas higher concentrations of extracellular 5-HT decreased 
both SERT expression and 5-HT uptake even below the baseline (63, 65, 76, 77). 
Moreover, platelet activation by the PKC pathway also causes a rapid (1 min) loss of 
transport activity, followed by a more delayed (10-30 min) internalization of SERT; 
these effects may be mediated by the interaction of SERT with regulatory proteins, 
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such as the adaptor protein Hic-5 (77). On the other hand, a direct interaction 
between SERT and the αIIbβ3 integrin has been shown to increase the level of SERT 
on the platelet surface and its transporter activity (78). 
SERT expression may also be genetically regulated. A frequent polymorphism in 
the 5’-flanking region of the SERT gene has been identified, which leads to the 
creation of short (S) and long alleles (L). The S allele has been associated with 
decreased SERT expression and 5-HT uptake (79-83). It is unclear, how this 
polymorphism is related to platelet reactivity, and cardiac risk. One study reported 
that patients carrying the S allele had an increased risk for cardiac events and a 
higher frequency of depressive symptoms (79). However, another study found that 
the existence of two S alleles in an individual appears to have a protective effect, 
delaying the onset of the first myocardial infarct, and this effect is more relevant 
among smokers (81). Abdelmalik et al. showed that, under SSRI treatment, carriers 
of two SS alleles had a lower platelet 5-HT concentration and an attenuated platelet 
aggregation (in PRP) in comparison to carriers with at least one L allele (80). 
However, two studies failed to associate this specific SERT polymorphism with 
platelet 5-HT concentrations among healthy individuals and with changes in platelet 
aggregation, bruising and spontaneous bleeding events during selective 5-HT 
reuptake inhibitor (SSRI) therapy (82, 83). 
 
1.6.2 Effects of selective serotonin reuptake inhibitors (SSRIs) on platelets 
Treatment with SSRIs leads to reduced platelet 5-HT content by inhibiting the 
SERT-mediated 5-HT uptake; they could therefore affect platelet function (84, 85) 
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and impede vasoconstriction mediated by platelet-secreted 5-HT. Both effects could 
cause an increase of bleeding time. 
 Epidemiological studies 
A cohort study by Dalton et al reported increased risk of upper gastrointestinal 
bleeding in patients receiving SSRIs, especially when combined with non-steroidal 
anti-inflammatory drugs (NSAIDs) and low-dose aspirin (86). A case-control study by 
Opatrny et al demonstrated a small increased risk of gastrointestinal hemorrhage 
with SSRI use (87). Another cohort study in the Danish population also showed an 
increased post-surgical bleeding risk in breast cancer patients under SRRI treatment 
(88). Two retrospective case-control studies in the UK and Denmark also supported 
the statement that SSRIs, especially in combination with NSAIDs or low dose aspirin, 
increase the risk of gastrointestinal bleeding (89, 90). Similarly, a case-control study 
showed a protective effect of SSRI use against myocardial infarction (MI) (91), while 
a cohort study reported a reduced MI risk among depressive patients receiving SSRIs 
for at least 3 months (92). In a meta-analysis, depressive patients with coronary 
heart disease receiving SSRIs also demonstrated lower coronary heart disease 
readmission and mortality rates compared to placebo or no treatment (93). 
Yet other epidemiological studies did not confirm an increased bleeding risk 
during SSRI intake or a cardio-protective effect of SSRI treatment. In particular, a 
case control study by Carvajal et al failed to demonstrate a significant increase in 
gastrointestinal bleeding by SSRI treatment (94). Moreover, two other studies, a 
case-control study with short-term exposure to SSRIs and a cohort study in elderly 
patients, reported an increased MI risk after medication with SSRIs (95, 96). 
In vitro studies 
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Carneiro et al demonstrated that acute blockade of the platelet SERT with the 
SSRI citalopram in vitro attenuated the ADP-induced aggregation of washed platelets 
with normal intracellular stores of 5-HT (78). In another study, platelet incubation 
with citalopram in vitro also attenuated 5-HT dependent platelet aggregation in PRP, 
as measured by light transmittance aggregometry, and in flow experiments (97). 
Moreover, incubation with citalopram attenuated the peak of thrombin generated 
by 5-HT stimulation of platelets, and showed a tendency to inhibit 5-HT stimulated 
blood coagulation (97). On the other hand, a study using human washed platelets 
showed that fluoxetine augmented platelet aggregation induced by ADP, thrombin 
and PAR-1 and PAR-4 activators (98). 
1.7 Platelet protein serotonylation 
In 2002 Dale et al. showed that upon activation with a combination of strong 
agonists, such as collagen and thrombin, a fraction of platelets expressed on their 
surface α-granule factor V (FV) and other α-granule proteins, including 
fibrinogen/fibrin, vWf, fibronectin, α2-antiplasmin and thrombospondin (defined as 
COAT-platelets or more recently as coated-platelets) (99, 100). It was proposed that 
COAT-platelets form by 5-HT–mediated stabilization of the receptor-mediated 
binding of adhesive and procoagulant proteins on the platelet surface. It was 
reported that procoagulant proteins such as factor V and fibrinogen are covalently 
bound to 5-HT via a transglutaminase reaction (“serotonylation”, see below), and 
that both fibrinogen and thrombospondin are capable of binding serotonylated 
proteins. The interactions between these proteins and their platelet surface 
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receptors have been suggested to result in a stabilized network of proteins (“COAT”) 
on the platelet surface (99-101). 
Additionally, Walther et al. found evidence of protein serotonylation inside the 
platelets. They reported a rapid covalent transglutaminase-mediated binding of 
cytoplasmic 5-HT to the GTPases RhoA and Rab4, rendering the latter active and 
inducing α-granule secretion through cytoskeletal rearrangements. As compared 
with wild-type platelets, α-granule secretion was decreased in platelets from 
tryptophan hydroxylase 1 isoenzyme knock-out mice, which lack the ability to 
synthesize peripheral 5-HT but have normal levels of 5-HT in the CNS. The protein 
transamidation of 5-HT was termed by Walther et al as serotonylation (102). 
These proposed roles of platelet 5-HT by attaching covalently to platelet surface 
and cytoplasmic proteins are interesting, but they need to be confirmed by further 
investigations. If true, SSRI intake should reduce the number of COAT-platelets and 
inhibit α-granule secretion. Indeed, in an ex vivo study chronic blockade of SERT by 
SSRIs resulted in a lower number of COAT-platelets; this effect was however, barely 
significant (p=0.046) (103). Moreover, the reduction of COAT-platelets was not 
restricted to patients taking SSRIs, but was also found in patients treated with aspirin 
(103). Together these results should be considered with caution since the number of 
COAT-platelets varies in different patients very much (99, 103). Considering the 
possible functional role of intracellular protein serotonylation as suggested by 
Walther et al (102), a selective inhibition of α-granule secretion by SSRI intake has 
not been reported so far. 
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 1.8 Platelet 5-HT receptors 
1.8.1 The platelet 5-HT2A receptor 
As with the SERT, 5-HT2A receptor mRNA has been found to be expressed in 
platelets with identical splicing to the brain 5-HT2A receptor (52). 5-HT2A receptors 
are located on the platelet surface and are coupled preferentially via the Gq proteins, 
which signal to the IP3/PKC pathway leading to calcium mobilization (6, 52, 104). 
Therefore, 5-HT stored in platelet-dense granules and released from them upon 
platelet stimulation might serve as a feedback mediator by binding to 5-HT2A 
receptors on the platelet surface and support platelet aggregation (49). 
5-HT, when added alone in vitro, is a weak platelet agonist and has been 
reported to activate or not to activate platelets in blood (105, 106). However, 5-HT 
potentiates platelet aggregation when added together with other platelet stimuli 
such as ADP, epinephrine, collagen, thrombin and thromboxane A2 (97, 106, 107). 
Therefore, it is possible that 5-HT released from platelet dense granules could 
together with other platelet-released mediators (ADP, Thromboxane A2) 
synergistically mediate and amplify platelet aggregation. 
1.8.2 Effects of 5-HT2A receptor antagonists on platelets 
5-HT2A receptor antagonists block the binding of 5-HT to the 5-HT2A receptor 
and antagonize the subsequent 5-HT-dependent calcium mobilization and platelet 
activation. Various 5-HT2A receptor antagonists have been known for a long time to 
inhibit 5-HT-dependent platelet aggregation (105, 108-111). 5-HT2A receptor 
antagonists have unequivocally been shown to inhibit 5-HT-potentiated platelet 
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aggregation of PRP in humans and many other species in vitro and ex vivo: Two 
studies demonstrated an inhibition of 5-HT-potentiated platelet aggregation of 
human platelets by various 5-HT2A receptor antagonists by using light transmittance 
aggregometry (LTA) in PRP and by measuring platelet count in blood (109, 110). R-
96544 is a potent and selective 5-HT2A receptor antagonist, in comparison to 
sarpogrelate, a well-known 5-HT2A receptor antagonist, which is not as potent as R-
96544 and also has a high affinity for receptors other than 5-HT2A, namely α1-
adrenergic and histamine H1 receptors. R-96544 inhibited 5-HT-potentiated 
aggregation in vitro in a series of species, namely human, monkey, cat, rabbit, rat 
and mice platelets (112). The same study showed ex vivo inhibition of 5-HT–
potentiated platelet aggregation by intravenously administered R-96544 and R-
102444, another structurally similar 5-HT2A receptor antagonist, in rabbits and in 
rats (112). In a recent study, cyproheptadine and pizotifen, two antidepressant non-
selective 5-HT2A antagonists, reversed serotonin-enhanced ADP-induced platelet 
aggregation in vitro in humans and ex vivo in mice (113). Two other 5-HT2A receptor 
antagonists, SR 46349 and APD791, also inhibited the 5-HT-potentiated platelet 
aggregation in human, rabbit and dog platelets in vitro, as measured by LTA. Oral 
administration of these two agents also inhibited rabbit and dog platelets ex vivo 
(114, 115). Additionally, 5-HT2A antagonists attenuated 5-HT-potentiated 
thrombosis in an in vivo model in mice (116). Hence, platelet aggregation 
potentiated by exogenous 5-HT administration is sensitive to 5-HT2A receptor 
blockade in human and animal platelets, both in vitro and ex vivo. Platelet 
aggregation potentiated by exogenous 5-HT administration was usually the main 
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parameter measured when the antithrombotic effect of a 5-HT2A receptor 
antagonist was examined. 
Do 5-HT2A receptor antagonists inhibit platelet aggregation when no exogenous 
5-HT is added, after platelet activation with physiological stimuli? As far as animals 
are concerned, in one study a selective 5-HT2A antagonist (DV-7028) inhibited 
collagen-induced 5-HT secretion in washed platelets and collagen-induced platelet 
aggregation in PRP in rats in vitro (117). Furthermore, the 5-HT2A antagonist 
ketanserin alone or in combination with aspirin, inhibited the collagen-dependent 
platelet aggregation in cats ex vivo (107). Interestingly, quite a few studies have been 
conducted in vivo. Four studies reported an inhibitory effect of three different 5-
HT2A receptor antagonists in the Folts model of coronary occlusion in the dog (114, 
118-120). Herbert et al also reported that the 5-HT2A receptor antagonist SR 46349 
prolonged bleeding time and suppressed thrombosis in an arterio-venous shunt 
model in rabbits, where thrombosis was induced by vessel ligation plus 
administration of i.v. tissue thromboplastin (114). Similarly, in a study involving rats, 
Pawlak et al reported that the 5-HT2A receptor antagonist DV-7028 prolonged 
bleeding time and inhibited thrombus formation in the arterial occlusion model, 
though it did not prevent venous thrombosis (117). In mice a 5-HT2A receptor 
antagonism also prolonged the occlusion time of mesenteric arterial thrombosis 
induced by electric stimulation (116). Two antidepressant 5-HT2A antagonists, 
cyproheptadine and pizotifen, prolonged tail bleeding time and prolonged occlusion 
time in a carotid artery thrombosis model in mice in vivo (113). Thus, the 5-HT2A 
receptor plays an important role in vivo in various animal thrombosis models.  
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Studies investigating the inhibition of stimulus-induced human platelet activation 
by 5-HT2A receptor antagonists have provided conflicting results. Ketanserin did not 
affect ADP-, epinephrine-, thromboplastin-, and collagen-induced platelet 
aggregation in PRP in one study, but inhibited ADP-, epinephrine- and thrombin-
induced platelet aggregation in PRP in another (107, 121). In patients with Raynaud’s 
phenomenon long term intake of ketanserin left ex vivo collagen-, ADP- and even 5-
HT-induced aggregation in PRP unaffected (122). On the other hand, another set of 
patients with Raynaud’s phenomenon had prolonged bleeding time under ketanserin 
treatment, although no change in agonist-induced platelet aggregation before and 
during treatment was observed (123). Last but not least, treatment with ketanserin 
surprisingly reduced the rate of intraoperative blood loss during total hip 
arthroplasty in elderly patients (124). It may be that in human physiology it is only 
the vascular action and not the pro-aggregative action of 5-HT that is inhibited by 5-
HT2A antagonists. In summary, under physiologically relevant conditions, the 
antagonism of 5-HT2A receptors on animal platelets has provided us with results 
that in many cases were not confirmed in studies with human platelets.  
 It should be noted that the 5-HT2A receptor antagonist ketanserin, although 
clinically introduced in the 1980s for the treatment of hypertension, was soon 
abandoned because of its pro-arrhythmic properties. It was never used as an 
antiplatelet drug (108, 125). Nevertheless, research concerning new 5-HT2A receptor 
antagonists continues until now and suggests possible clinically relevant anti- 
platelet properties based mostly on animal studies (115, 118). 
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1.8.3 The platelet 5-HT4 platelet receptor 
Recently evidence for the expression of 5-HT-4 receptors has been described in 
human platelets (126). 5-HT4 receptors are Gs-coupled receptors and activate 
adenylyl cyclase, thus increasing the intracellular content of cAMP (127). This second 
messenger cAMP inhibits platelet activation (36, 46) and therefore the stimulation of 
platelet 5-HT4 receptors should lead to inhibition of platelet aggregation. However, 
tegaserod, a potent 5-HT4 receptor agonist enhanced ADP-, collagen-, epinephrine- 
and 5-HT-induced aggregation in PRP in vitro as measured by light transmittance 
aggregometry (LTA) (126). A more recent study using the same methodology failed 
to reproduce the stimulating effect of tegaserod on ADP-induced aggregation (128). 
1.9 Topic and question of the dissertation 
Serotonin is stored in platelets and may alter their function; therefore, we aimed 
to investigate the effect of SSRIs on platelet aggregation, and to understand the role 
of platelet 5-HT2A and 5-HT4 receptors for platelet function. 
SSRIs are at present the most commonly prescribed antidepressive drugs 
worldwide. Many, but not all studies have shown an increase in bleeding 
complications and a decrease in the incidence of myocardial infarction following SSRI 
therapy (94-96). In vitro, few studies using PRP demonstrated an inhibitory effect of 
SSRIs on platelet aggregation, whilst another one using washed platelets showed the 
opposite effect (78, 97, 98). We decided to study the in vitro effects of SSRIs on 
platelet aggregation under more relevant physiological conditions, i.e. in human 
blood. 
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Although orally effective platelet inhibitors such as aspirin and P2Y12 receptor 
antagonists (clopidogrel and prasugrel), are currently available for the treatment of 
atherothrombosis and its sequelae (myocardial infarction, ischemic stroke), new 
antiplatelet therapies are needed that lack the bleeding complications of the 
currently used anti-platelet drugs. The findings of early and recent animal studies ex 
vivo and in vivo suggest that the blockade of the platelet 5-HT2A receptors might be 
a good target for future anti-platelet therapy. However, studies with human blood 
and physiological platelet stimuli provided conflicting results. We, therefore, decided 
to investigate for the first time, in a comprehensive study the effects of 5-HT2A 
antagonists on platelet function in human blood in vitro under static and arterial 
flow conditions, after stimulation with physiologic agonists and a 
pathophysiologically relevant platelet agonist, i.e. human atherosclerotic plaque 
homogenate. 
Very recently the expression of 5-HT4 receptors on platelets has been reported. 
Their role for platelet function is unclear. We therefore investigated the effect of 5-
HT4 receptor agonists and antagonists in human blood. The aims and experimental 
work program of the dissertation are divided into three sections: 
1) Effect of SSRI on platelet aggregation in human blood 
2) Role of the 5-HT2A receptor for platelet function in human blood 
3) Role of the 5-HT4 receptor for platelet aggregation in human blood. 
The overall goal of the dissertation is to provide a comprehensive, better 
understanding of the 5-HT related platelet physiology, in order to identify possible 
adverse effects of 5-HT-related medications targeting other systems and to explore 
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whether platelet 5-HT receptors could be possible new targets for anti-platelet 
therapy. 
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2. Materials and methods 
 
2.1 Materials 
2.1.1 Devices 
 
Type of device Name and origin  
  
Light Transmission 
Aggregometer 
Lumi-Aggregometer (Chronolog, Havertown, PA) 
Impedance-Aggregometer Multiplate®, (Dynabyte Medical, München, 
Germany) 
Microscope Inverted fluorescence microscope (Nikon 
TE2000E-PFS, Tokyo, Japan) 
Microscope camera CCD camera (CooLSNAP HQ2, Tuscon, AZ, USA) 
Shear-stress platelet function 
analyzer  
Cone and plate analyzer Impact-R, (Matis-
Medical, Brussels, Belgium) 
 
Parallel plate flow chamber Sticky-Slide I0.1 Luer (ibidi GmbH, Martinsried, 
Germany) 
Flow analysis pump system ibidi pump system (ibidi GmbH, Martinsried, 
Germany) 
 
2.1.2 Disposable materials 
 
Type of material Origin 
  
Butterfly needle (19-Gauge) Intermedica GmbH (Mainz, Deutschland) 
Lumi-aggregomter cuvettes, 450 
µl 
Chronolog, Havertown, PA 
Lumi-aggregometer disposable 
siliconized stir bars 
Chronolog, Havertown, PA 
Multiplate®-test cells  Dynabyte Medical (München, Germany) 
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2.1.3 Chemicals 
 
Chemical Origin Stock concentration, 
dilution buffer  
   
(±)-epinephrine Sigma-Aldrich (Taufkirchen, 
Germany) 
1 M epinephrine in 1 M 
HCl, further dilution in 
NaCl 0.9%  
 
Adenosine 5′-triphosphate 
disodium salt hydrate (ATP) 
Sigma-Aldrich (Taufkirchen, 
Germany) 
 
0.9 % NaCl 
Adenosine 5'-diphosphate 
sodium salt (ADP) 
Sigma-Aldrich (Taufkirchen, 
Germany) 
 
0.9 % NaCl 
ASA control 
(Acetyl salicylic acid) 
Dynabyte (Munich, 
Germany) 
Distilled H2O;  5.4 mM 
 
CJ-033,466 
(5-HT4 receptor agonist) 
 
Tocris bioscience (Ellisville, 
MO, USA) 
 
 
DMSO to 100 mM,  further 
dilution in 0.9% NaCl  
Collagen Horm® Nycomed Pharma (Munich, 
Germany) 
 
SKF solution (supplied 
within Collagen Horm® 
package) 
Fluoxetine hydrochloride Sigma-Aldrich (Taufkirchen, 
Germany) 
 
0.9 % NaCl 
GR113808 
(5-HT4 receptor antagonist) 
Tocris bioscience (Ellisville, 
MO, USA) 
25 mM GR 113808 in 1 M 
HCl, further dilution in 
0.9%NaCl  
Ketanserin (+)-tartrate salt Sigma-Aldrich (Taufkirchen, 
Germany) 
10 mM ketanserin in 0.1 
M HCl, further dilution in 
0.9% NaCl  
Luciferin-luciferase reagent Chronolog  (Chrono-Lume®, 
Havertown, PA, USA) 
 
Distilled H2O 
Quinacrine dihydrochloride 
(mepacrine) 
Sigma-Aldrich (Taufkirchen, 
Germany) 
 
0.9 % NaCl 
R-96544 hydrochloride 
(5-HT2A receptor 
antagonist) 
Tocris bioscience (Ellisville, 
MO, USA) 
 
0.9 % NaCl 
Recombinant lepirudin 
(hirudin, Refludan®) 
 
Schering AG(Germany) 0.9 % NaCl  
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RS 23597-190 hydrochloride 
(5-HT4 receptor antagonist) 
Tocris bioscience (Ellisville, 
MO, USA) 
 
0.9 % NaCl 
Sarpogrelate hydrochloride  
(5-HT2A receptor 
antagonist) 
Tocris bioscience (Ellisville, 
MO, USA) 
 
0.9 % NaCl 
Serotonin hydrochloride (5-
HT) 
Sigma-Aldrich (Taufkirchen, 
Germany) 
 
0.9 % NaCl 
TRAP-6 (PAR-1 agonist) Bachem (Weil am Rhein, 
Germany) 
0.9 % NaCl 
 
 
 
2.1.4 Buffers 
 
Buffer Origin 
  
Sodiumchloride (NaCl) 0.9 %   
Dimethylsulfoxid (DMSO) Calbiochem  
Dulbecco’s Phosphate buffered Saline (PBS) Sigma-Aldrich (Taufkirchen, Germany) 
Hydrochloric acid (HCl) fuming 37%  Merck (Darmstadt, Germany) 
 
 
2.2 Methods 
2.2.1 Blood collection  
Blood was obtained from healthy volunteers, who denied taking any medication 
affecting platelet function for at least two weeks preceding the experiments. 
Informed consent was obtained in accordance with the Helsinki protocol. 
Recombinant hirudin was dissolved in 0.9% NaCl solution to a concentration of 2000 
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U/ml (130 µg/ml). Blood was obtained by venipuncture using a 19-gauge needle and 
a 10 – 50 ml plastic syringe containing one tenth volume of recombinant hirudin 
(final concentration in blood ~200 U/ml; 13 µg/ml). The syringe was then gently 
moved in order to allow a homogeneous distribution of blood and anticoagulant. In 
order to avoid platelet activation by subendothelial tissue thromboplastin, the first 3 
ml of blood were drawn in a separate syringe and were subsequently discarded 
(129). 
Aggregation measurements, dense granule secretion measurements and flow 
experiments were performed between 30 minutes and 4 hours after venipuncture. 
Only in one set of experiments we examined the aggregation induced by 5-HT alone 
early after venipuncture. In this set of experiments aggregation measurements were 
conducted between 5 min and 30 min after venipuncture, as indicated in the Results 
section.  
2.2.2 Preparation and preservation of human atheromatous plaque 
homogenate 
Atherosclerotic plaques were obtained from patients who underwent 
endarterectomy for high grade carotid artery stenosis with en bloc preservation of 
the tissue structure (130). Patient consent was obtained and approved by the Ethics 
Committee of the Faculty of Medicine of the University of Munich. After intra-
operative removal, plaque specimens were immediately shock frozen in liquid N2, 
and stored at -80°C. Under sterile conditions, atheromatous plaques were carefully 
dissected from other regions of the atherosclerotic tissue specimens (130). The 
plaque samples were then weighed, homogenized and the concentration was 
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adjusted to 100 mg wet weight/ml. The plaque homogenates were kept at –80°C 
until further experimentation (131, 132). Plaque homogenates from 5 to 7 individual 
patients were pooled and used for the experiments. 
2.2.3 Whole blood platelet aggregation 
Whole blood platelet aggregation was determined by multiple electrode 
aggregometry (MEA) using the Multiplate® device from Dynabyte Medical (Munich, 
Germany) (Figure 2.1) 
 
Figure 2.1: The Multiplate® device. The central unit of the Multiplate®-system has 5 positions for 
measuring plaletet aggregation. Blood can be warmed at 37oC by a heated metalic plaque containing 
the 5 cuvette positions. A screen enables the control and the visualization of the experiments (left). 
The  Multiplate®-cuvette has a stir bar and two pairs of electrodes (right). For measurement of 
aggregation, one end of the electrodes is connected to the main unit of the Multiplate®-system, and 
the other end of the electrodes is immersed in blood. The measurement of electric impedance 
between the anode and cathode of the two electrode pairs provides two independent values of 
aggregation in the same cuvette. Modified image from www.multiplate.net (133).  
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Figure 2.2: Principle of impedance aggregometry. Inactive platelets (i) that get activated by the 
presence of platelet stimuli (ii) adhere and aggregate onto the electrodes (iii) thereby creating a 
platelet layer which elevates the electric impedance between the two electrodes.  
 
This device detects the increase of electrical impedance due to the adhesion and 
aggregation of platelets on the surface of two independent electrode pairs in the 
test cuvette (Fig 2.2).  
Samples (0.6 ml) contained a 1:1 mixture of 0.9% NaCl and anticoagulated blood 
which were stirred in the presence or absence of SSRIs, 5-HT2A receptor antagonists, 
5-HT4 receptor antagonists or solvent at 37°C for 3 min in the cuvettes. In some 
experiments different pre-incubation periods of 13 minutes or 5 seconds were used 
as described in the results section. At the end of pre-incubation, platelet stimuli 
(serotonin, epinephrine, TRAP, arachidonic acid, collagen, plaque homogenate) or 
solvent were added, and the measurements were started. The increase in electrical 
impedance was recorded continuously for 5 min. The mean value of the two 
independent determinations is expressed in arbitrary units over time (AU* min). 
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2.2.4 Measurement of ATP secretion 
ATP secretion was measured using the Lumi-Aggregometer from Chronolog. This 
device measures the luminescence emitted when ATP interacts with the luciferin-
luciferase reagent. The firefly luciferase catalyzes a two-step chemical reaction (134): 
 
Luciferin + ATP                                              Luciferil-adenylate  (1st step) 
 
Luciferil-adenylate                                    Oxyluciferin + CO2 + AMP + light (2
nd step) 
 
In this way, ATP secreted from platelet dense granules upon platelet activation in 
response to various stimuli is measured. The measurement is normally applied in 
platelet-rich plasma, but can also be performed in blood (135, 136). 
 
Hirudin-anticoagulated blood (200 µl) was diluted 1:1 with normal saline solution 
in a Chronolog cuvette containing a stir bar and gently mixed with a 200 µl pipette. 
Stirring speed was set to 800 rpm. The diluted hirudinized blood was incubated for 
30 sec at 37°C with 50 µl luciferin-luciferase reagent. Then ketanserin (1 µM) or 
solvent was added, the samples were incubated for 3 min at 37°C and then exposed 
to platelet stimuli or solvent. The increase of luminescence over time was recorded 
by a 2 channel recorder. For each experiment, the maximal increases of 
luminescence were translated into ATP concentration by performing a standard 
curve with increasing concentrations of ATP added to the blood/NaCl samples. 
 
Luciferase 
Luciferase + O2 
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Figure 2.3: Tracing of ATP secretion as measured by luminescence. Platelets were activated by 
addition of a low dose of collagen (0.5 µg/ml) to diluted blood. The rise of activated platelets 
correlates with platelet ATP secretion from dense granules, which is measured by luminescence in the 
presence of luciferin-luciferase reagent. After a plateau of maximal ATP secretion the ATP 
concentration decreases.  
2.2.5 Plaque-induced platelet adhesion and thrombus formation under flow 
In order to assess the effect of the 5-HT2A receptor antagonist ketanserin on 
platelet aggregation under more relevant physiological conditions, we performed 
platelet adhesion and aggregation studies under arterial flow conditions. For this 
purpose the pump system and parallel plate flow chambers from ibidi GmbH 
(Martinsried, Germany) were used. The pump applies a computer controlled amount 
of air pressure through a plastic tube into an upright syringe containing whole blood. 
The blood flows through a parallel plate flow chamber with a defined flow rate 
which determines the shear rate and shear stress, and is collected in a second 
syringe. 
As parallel plate flow chamber, the Ibidi Sticky-Slide I0.1 Luer) of 0.1 mm height, 5 
mm width and 50 mm length was used. It consists of a U-shaped glass slide with self-
adhesive underside onto which a thin glass coverslip is attached by applying firm 
pressure. The glass coverslip was coated before with plaque homogenate (Fig. 2.5).   
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Figure 2.5: Preparation and profile of the parallel plate flow chamber containing human plaque. 
The chamber consists of two parts: A thin glass coverslip coated with human plaque homogenate 
(lower part), and a bottomless ibidi slide with self-adhesive underside (upper part). The thin glass 
coverslip was coated with 20µl of human atheromatous plaque (5mg/ml) (i) and was left to dry (ii). 
The two parts of the slide were joined by applying firm pressure (ii) to assemble the flow chamber(iii). 
 
Each glass coverslip (24x60 mm, thickness 0.16-0.19mm; Menzel Gläser, 
Braunschweig, Germany) was first washed with isopropranolol and dried. The slides 
were then coated with 20 µl of diluted human atheromatous plaque homogenate 
(concentration 5 mg/ml; diluted with PBS) and was left to dry at room temperature 
overnight. 
The plaque-coated chambers were mounted on the stage of an inverse 
microscope (Nikon TE2000E-PFS, Tokyo, Japan) equipped with an incubation 
chamber (37°C). Before the experiment, the chambers were perfused with PBS for 2 
min at a wall shear rate of 500 s-1. Mepacrine (10 µM) was added to blood (37°C, 3 
min) in order to visualize platelets by fluorescence. Then, the hirudin-anticoagulated 
blood was transferred to the inlet syringe, and chambers were perfused for 10 min 
at a wall shear rate of 500 s-1 (flow 247 µl/min). Blood was preincubated with or 
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without the 5-HT2A receptor antagonist ketanserin (1 µM) at 37°C for 3 min prior to 
start of flow. 
Fluorescence microscopy (excitation: 485 +/- 25 nm; emission: 528 +/- 38nm; x10 
objective) was used for visualization of mepacrine-labeled platelet adhesion and 
aggregation onto plaque homogenate in flowing blood. Platelet deposition was 
recorded in real-time with a CCD camera. For each flow experiment, surface fields of 
the size of 538.000 µm2 were recorded. Video fluorescent images were analyzed off-
stage with the software NIS-element 3.1 version (Nikon). In each field, the area 
covered by atherosclerotic plaque prior to the flow, and the area covered by platelet 
thrombi plus atherosclerotic plaque after each minute were analyzed. The area 
covered by atherosclerotic plaque was subtracted from the total fluorescent area in 
order to calculate the platelet coverage. 
2.2.6 Shear-induced platelet adhesion and aggregation 
Shear-induced platelet adhesion and aggregate formation was measured in the 
cone and plate analyzer Impact-R (Matis-Medical, Brussels, Belgium) (137). Blood 
samples (0.2 ml), in the presence or absence of 10 µM ketanserin, were placed on 
polystyrene surface plates and subjected to flow using a rotating teflon cone. The 
rotation induced a constant fluid shear stress over the entire plate surface. Wells 
were washed with PBS and stained with May–Grünwald stain, and analyzed with an 
inverted light microscope (137). The shear-induced platelet adhesion and 
aggregation was evaluated by platelet surface coverage and average size of platelet 
aggregates. In two sets of experiments two different shear rates of 600 s-1 or 1200 s-1 
were applied. 
[38] 
 
These experiments were conducted in cooperation with Dr Ela Shai and Prof. 
David Varon (Coagulation Unit, Hadassah-Hebrew University Medical Center, 
Jerusalem, Israel). 
2.2.7 Statistical analysis 
Results are given as mean ± SD or ± SEM from n experiments conducted with 
blood from different donors. Statistical significance was assessed by paired two-
sided t-test, unpaired two-sided t-test or unpaired rank sum test (Mann-Whitney), 
where applicable. Statistical analysis was performed using Sigma-Plot 11.0. For all 
analyses a level of significance 5% (p<0.05) was adopted. 
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3. Results 
3.1 Role of the serotonin reuptake transporter (SERT) for platelet 
aggregation in blood 
3.1.1 5-HT potentiates the epinephrine-induced platelet aggregation 
We examined the stimulatory effect of 5-HT, epinephrine and its combination on 
platelet aggregation as measured by MEA in whole blood. A set of experiments after 
3 min of platelet pre-incubation at 37oC was conducted. The results are presented in 
Figure 3.1.  
Figure 3.1: Potentiation of epinephrine-induced platelet aggregation by 5-HT. Hirudin-
anticoagulated blood was incubated for 3 min under stirring conditions at 37°C before addition of 
platelet stimuli. The platelet aggregation response was recorded by MEA for 5 min. Results are 
expressed as mean values ± SD (n=9 with different blood donors). * refers to P < 0.01.  
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Blood that is not agonist-stimulated (column designated as control) shows only a 
small amount of aggregation. This response is commonly described as spontaneous 
platelet aggregation.  
Platelet aggregation measured after addition of 10 μM 5-HT did not differ 
significantly from control (56 ± 29 vs 47 ± 18 AU*min respectively, values are mean ± 
SD; P = 0.24). Addition of 10 μΜ epinephrine alone induced a small increase of 
platelet aggregation in comparison to control (76 ± 34 vs. 47 ± 18 AU*min 
respectively, values are mean ± SD; P < 0.01) (Figure 3.1). 5-HT (10µM) added 
simultaneously with epinephrine (10 μM) was able to potentiate the epinephrine-
induced aggregation from a mean ± SD of 76 ± 34 AU*min to 327 ± 143 AU*min (P < 
0.01) (Figure 3.1).  
Commonly, as described in the Methods section, blood is left after venipuncture 
for 30 min at room temperature before measuring platelet aggregation. 
Hypothetically, released 5-HT from platelets activated by the venipuncture might 
cause homologous desensitization of the 5-HT receptor(s) over time and, therefore, 
a direct platelet response is not detectable after 30 min. Yet, some response to 5-HT 
might be detectable early after venipuncture, where receptor desensitization might 
be less pronounced. Therefore, we further examined if 5-HT alone induced 
aggregation early after venipuncture. Experiments were conducted 5, 15 and 30 min 
after venipuncture. However, 5-HT did not stimulate platelet aggregation at any time 
after venipuncture. Spontaneous aggregation (control) and platelet aggregation after 
5-HT admission did not differ during the first 30 min after venipuncture (Figure 3.2). 
[41] 
 
 
Figure 3.2: Effect of 5-HT on whole blood platelet aggregation 5, 15 and 30 minutes after 
venipuncture. Hirudin-anticoagulated blood was incubated for 3 min with stirring at 37°C before 
addition of 10 µM 5-ΗΤ. Experiments were started 5, 15 and 30 minutes after venipuncture. Results 
are expressed as mean values ± SD (n=10 with different blood donors). 
 
The good potentiation of epinephrine-induced platelet aggregation by 5-HT, 
combined with the fact that epinephrine is a weak mediator of platelet aggregation 
with a distinct signal transduction pathway from 5-HT, suggests that the concomitant 
use of 5-HT + epinephrine is a good model to study inhibitors of the serotonergic 
pathway of platelet aggregation. 
3.1.2 The SERT-inhibitor fluoxetine inhibits the 5-HT-induced potentiation of 
platelet aggregation 
In order to assess the effect of 5-HT reuptake transporter inhibitors (SSRIs) on 5-
HT-dependent platelet aggregation in vitro, we used a 10 μM concentration of the 
SSRI fluoxetine, the highest achievable plasma concentration after clinical 
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administration (138). Fluoxetine is one of the oldest and best studied SSRIs with high 
affinity for the 5-HT reuptake transporter (89, 91). 
Pre-treatment of whole blood with 10 µM fluoxetine for 3 minutes inhibited 
partially 5-HT-dependent platelet aggregation from 327 ± 143 to 195 ± 90 AU*min 
(mean ± SD; P < 0.01) (Figure 3.3). 
In another set of experiments, we addressed the question whether extending the 
time of blood pre-incubation with fluoxetine might enhance its inhibition of 5-HT-
dependent platelet aggregation. Whole blood was incubated for 10 minutes at 37°C 
without stirring with fluoxetine or solvent, prior to dilution with 0.9% NaCl and 
stirring for 3 min. Additional pre-treatment of whole blood with 10 µM fluoxetine for 
10 minutes also reduced 5-HT-dependent platelet aggregation: from 163 ± 76 
AU*min to 101 ± 45 AU*min (mean ± SD; P < 0.05) (Figure 3.3). Since the synergistic 
effect of 5-HT and epinephrine on platelet aggregation was clearly less in this set of 
experiments, it cannot be concluded that inhibition of 5-HT-dependent platelet 
aggregation by fluoxetine was more pronounced. In a third set of experiments, we 
tested if fluoxetine had an immediate effect on platelet aggregation. In such a case, 
the inhibitory effect on platelet aggregation should not be attributed to the 
modification of SERT-function by fluoxetine (and the subsequent change in intra- and 
extracellular 5-HT concentrations), but rather to the antagonism of 5HT2A receptors. 
To test this hypothesis 10 µM fluoxetine was added just 5 seconds prior to addition 
of 5-HT plus epinephrine. This minimal incubation time with fluoxetine inhibited 
aggregation from 357 ± 209 to 216 ± 179 AU*min (mean ± SD; P < 0.01) (Figure 3.4). 
The mean inhibition of aggregation after incubating whole blood with 10 μΜ 
fluoxetine for either 5 seconds, 3 min or 13 min, was 49 ± 31 %, 38 ± 17 % and 34 ± 
[43] 
 
21 %, respectively (mean ± SD, no statistical significance between different 
incubation periods for unpaired two-sided t test and Mann-Whitney rank sum test). 
The corresponding spontaneous platelet aggregation (controls) for the three sets of 
experiments were 21 ± 22, 47 ± 18 and 41 ± 15 AU*min (mean ± SD) and the 
difference was statistically significant between the first two sets (P<0.05, unpaired 
two-sided t test). After subtracting the amount of spontaneous platelet aggregation 
from all other experiment results, inhibition was 53 ± 34 %, 45 ± 19 % and 53 ± 35 % 
for 5 seconds, 3 min or 13 min respectively (mean ± SD, no statistical significance 
between different incubation periods for unpaired two-sided t test and Mann-
Whitney rank sum test). Thus, the inhibition of 5-HT potentiated platelet aggregation 
was not different for the three incubation periods with 10µM fluoxetine.  
A concentration response curve of fluoxetine on aggregation induced by 10 µM 
5-HT plus epinephrine 10 µM was performed (Figure 3.5). Concentrations of 1 to 100 
µM fluoxetine were used. The minimal concentration of fluoxetine that significantly 
inhibited 5-HT potentiated platelet aggregation was 5 µM and the inhibition by 100 
µM fluoxetine was almost complete. The IC50 of fluoxetine was calculated with a four 
parameter sigmoidal model at 20 µM. In conclusion, the results indicate that 
fluoxetine, an SSRI, immediately inhibits 5-HT-potentiated platelet aggregation in 
whole blood in vitro most likely by an antagonism of platelet 5HT2A receptors. 
 
 
[44] 
 
Figure 3.3: Effect of 3 and 13 minutes pre-incubation with 10 µM fluoxetine on 5-HT-potentiated 
platelet aggregation in whole blood. Hirudin-anticoagulated blood was diluted 1:1 with saline, and 
incubated in the absence or presence of 10 μM fluoxetine for 3 min (3 minutes incubation). 
Alternatively, in the absence or presence of 10 μΜ fluoxetine, hirudin-anticoagulated blood was 
incubated for 10 min at 37°C without stirring, then diluted 1:1 with saline, and incubated for 3 min 
with stirring at 37°C (13 minutes incubation). 5-HT (10 μM) plus epinephrine (10 μM) were added 
thereafter. Results are expressed as mean values ± SD (n=9 for and n=8 with different blood donors 
for 3 and 13 min incubation respectively). * refers to P < 0.05 and ** refers to P < 0.01.  
 
 
Figure 3.4: Effect of 5 seconds incubation with 10 µM fluoxetine on 5-HT-potentiated platelet 
aggregation in whole blood. Hirudin-anticoagulated blood was incubated for 3 min at 37°C; 10 µM 
fluoxetine or solvent was added 5 seconds before addition of the platelet stimuli. The results are 
expressed as mean values ± SD (n=6 with different blood donors). ** refers to P < 0.01. 
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Figure 3.5: Effect of different concentrations of fluoxetine on 5-HT-potentiated platelet 
aggregation in whole blood. Hirudin-anticoagulated blood was incubated in the absence or presence 
of different concentrations of fluoxetine for 3 min at 37°C before addition of platelet stimuli. Results 
are expressed as percent of inhibition of platelet aggregation, after spontaneous aggregation was 
subtracted. * refers to P < 0.05 and ** refers to P < 0.01 for paired two sided t-test. 
 
3.1.3 No effect of fluoxetine on stimulus-dependent platelet aggregation 
Next we investigated the effects of the SSRI fluoxetine on a variety of 
physiologically and pathophysiologically relevant platelet agonists, namely ADP, 
TRAP, collagen and human atherosclerotic plaque homogenate. All these stimuli are 
known to increase the secretion of 5HT from platelet dense granules; fluoxetine 
could interfere with the action of released 5HT. 
Addition of ADP induced a moderate platelet aggregation at a concentration of 1 
µM and high platelet aggregation at a concentration of 5 µM. In both cases, 
incubation of whole blood with fluoxetine for 3 minutes did not inhibit the platelet 
aggregation induced by these two different concentrations of ADP (Figure 3.6). 
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Figure 3.6: Effect of fluoxetine on ADP-induced platelet aggregation in whole blood. Hirudin-
anticoagulated blood was diluted 1:1 with saline, and incubated in the absence or presence of 10 μM 
fluoxetine for 3 min (3 minutes incubation). Alternatively, in the absence or presence of 10 μΜ 
fluoxetine, hirudin-anticoagulated blood was incubated for 10 min at 37°C without stirring, then 
diluted 1:1 with saline, and incubated for 3 min with stirring at 37°C (13 minutes incubation). ADP was 
added thereafter. Results are expressed as mean values ± SD (n=5 with different blood donors). No 
effect of fluoxetine was observed. 
 
When whole blood was incubated additionally for 10 minutes without stirring at 
37°C, platelet aggregation induced by 1 µM and 5 µM ADP was less as compared to 
the experiments with a shorter incubation period. There was again no effect of 
fluoxetine in this set of experiments (Figure 3.6). 
0
100
200
300
400
500
600
ADP 1 µM ADP 5 µM ADP 1 µM ADP 5 µM
A
gg
re
g
at
io
n
, A
U
*m
in
3 min incubation                      13 min incubation
with fluoxetine
without fluoxetine
[47] 
 
 
Figure 3.7: Effect of fluoxetine on TRAP-induced platelet aggregation in whole blood. Hirudin-
anticoagulated blood was diluted 1:1 with saline, and incubated in the absence or presence of 10 μM 
fluoxetine for 3 min (3 minutes incubation). Alternatively, in the absence or presence of 10 μΜ 
fluoxetine, hirudin-anticoagulated blood was incubated for 10 min at 37°C without stirring, then 
diluted 1:1 with saline, and incubated for 3 min with stirring at 37°C (13 minutes incubation). TRAP 
was added thereafter. Results are expressed as mean values ± SD (n=5 with different blood donors). 
No effect of fluoxetine was observed. 
 
Next, the effect of fluoxetine on platelet aggregation induced by the thrombin 
receptor activating peptide (TRAP) was tested (Figure 3.7). TRAP activates PAR-1, the 
main thrombin receptor of human platelets. It was found that 2 µM TRAP induced a 
modest platelet aggregation, whilst 5 µM TRAP induced a potent platelet 
aggregation. No effect of fluoxetine was observed on the aggregation induced by 
either concentration of TRAP used (2 µM and 5 µM) with both incubation periods (3 
and 13 minutes respectively) (Figure 3.7). 
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Figure 3.8: Effect of fluoxetine on collagen and plaque-induced platelet aggregation in whole blood. 
Hirudin-anticoagulated blood was diluted 1:1 with saline, and incubated in the absence or presence of 
10 μM fluoxetine for 3 min (3 minutes incubation). Alternatively, in the absence or presence of 10 μΜ 
fluoxetine, hirudin-anticoagulated blood was incubated for 10 min at 37°C without stirring, then 
diluted 1:1 with saline, and incubated for 3 min with stirring at 37°C (13 minutes incubation). 
Thereafter 0.5 µg/ml collagen or 2.5 µl human plaque homogenate (final concentration of 0.42 
mg/ml) were added. Results are expressed as mean values ± SD (n=5 with different blood donors). No 
effect of fluoxetine was observed. 
 
We also investigated the effect of the SSRI fluoxetine on platelet aggregation 
induced by collagen, a main substance of the subendothelial matrix and a main 
initiator of platelet aggregation. The relatively high platelet aggregation induced by 
0.5 µg/ml collagen could not be inhibited by incubation with 10 µM fluoxetine for 3 
or 13 minutes (Figure 3.8). 
Last but not least, we investigated the effect of fluoxetine on the platelet 
aggregation induced by the pathophysiologically relevant platelet agonist, human 
atheromatous plaque homogenate. Platelet aggregation induced by 2.5 µl of plaque 
homogenate (final concentration of 0.42 mg/ml) was again not inhibited by 
incubation with 10 µM fluoxetine for 3 or 13 minutes (Figure 3.8). 
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In conclusion, fluoxetine was able to inhibit only the 5-HT-potentiated platelet 
aggregation in blood, but it did not interfere with the aggregation response induced 
by a variety of other platelet stimuli, which play a significant physiological and 
pathophysiological role on platelet aggregation. 
3.1.4 Effects of the combination of acetylsalicylic acid and fluoxetine on 
platelet aggregation 
Fluoxetine alone did not inhibit platelet aggregation, except the one dependent 
on exogenous 5-HT administration. Subsequently, we investigated if fluoxetine could 
potentiate platelet inhibition caused by the clinically relevant antiplatelet 
acetylsalicylic acid (ASA, aspirin). Such an interaction could be of clinical significance, 
especially if it occurred when atherosclerotic plaque was used as a platelet stimulus.  
Figure 3.9: Fluoxetine does not potentiate the inhibition of plaque-induced aggregation by 
acetylsalicylic acid (ASA). Hirudin-anticoagulated blood was incubated in the absence or presence of 
10 μM fluoxetine, 5.4 mM acetylsalicylic acid (ASA) or their combination for 3 min at 37°C before 
addition of 2.5 µl of human atherosclerotic plaque homogenate (final concentration of 0.42 mg/ml). 
Results are expressed as mean values ± SD (n=6 with different blood donors). Fluoxetine did not 
inhibit plaque-dependent aggregation alone or in the presence of ASA. * refers to P < 0.05. 
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Incubation with ASA inhibited the plaque-induced aggregation significantly. 
Platelet aggregation response was 200 ± 55 to 86 ± 29 AU*min in the absence or 
presence of ASA respectively (mean ± SD; P < 0.05) (Figure 3.9). As observed in 
previous experiments, 10 µM fluoxetine did not inhibit the plaque-induced platelet 
aggregation. Moreover the plaque-induced platelet aggregation observed with 
inhibition by ASA plus fluoxetine did not differ from that observed by ASA alone (70 
± 35 and 86 ± 29 AU*min respectively, P = 0.26) (Figure 3.9). 
 
We also investigated the inhibitory effect of ASA alone and fluoxetine plus ASA 
on the 5-HT-potentiated aggregation in order to assess any possible synergism. 
As expected, 10 µM fluoxetine reduced platelet aggregation induced by 5-HT plus 
epinephrine from 379 ± 156 to 307 ± 166 AU*min (mean ± SD; P < 0.05) (Figure 
3.10). ASA had no effect on 5-HT-potentiated aggregation (366 ± 166 to 379 ± 156 
AU*min with and without 5.4 mM ASA, P = 0.32) (Figure 3.10). Moreover, the 
inhibitory effect of fluoxetine alone did not differ from that of the combination of 
ASA plus fluoxetine (307 ± 166 to 320 ± 158 AU*min respectively, P = 0.48) (Figure 
3.10). 
 
[51] 
 
 
Figure 3.10: Aspirin does not potentiate the inhibition of 5-HT-dependent aggregation by 
fluoxetine. Hirudin-anticoagulated blood was incubated in the absence or presence of 10 μM 
fluoxetine, 5.4 mM acetylsalicylic acid (ASA) or their combination for 3 min at 37°C before addition of 
10 µM 5-HT plus 10 µM epinephrine. Results are expressed as mean values ± SD (n=6 with different 
blood donors). ASA did not inhibit 5-HT-dependent aggregation alone or in the presence of fluoxetine. 
P refers to paired two-sided t-test. 
 
In conclusion, plaque-induced platelet aggregation was inhibited by ASA, and 5-
HT dependent platelet aggregation was inhibited by fluoxetine, but their 
combination did not result in a further inhibition on either type of stimulus-induced 
platelet aggregation. 
 
3.1.5 Role of different blood pre-incubation time periods on spontaneous and 
stimulus-induced platelet aggregation 
As described in the previous sections, we conducted two sets of experiments to 
examine the effect of fluoxetine on each different platelet agonist. In the first set of 
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experiments we used the standard procedure of multiple electrode aggregometry, 
that is we incubated blood diluted 1:1 with saline at 37oC for 3 minutes under 
stirring conditions prior to addition of the platelet agonist. In the second set of 
experiments whole blood was pre-incubated for 10 minutes without stirring at 37oC, 
and then diluted 1:1 with saline, and incubated for 3 minutes whilst stirring prior to 
addition of the platelet agonist. Thus, in the second set of experiments blood was 
exposed at 37oC for an additional time period of 10 minutes. We observed that for 
certain platelet stimuli the additional incubation time period of blood at 37°C 
resulted in a decrease of platelet aggregation. 
 
Figure 3.11: Effect of different incubation periods at 37
o
C on platelet aggregation after addition of 
buffer (control), 5-HT, epinephrine, 5-HT plus epinephrine and ADP. Hirudin-anticoagulated blood 
was diluted 1:1 with saline, and incubated for 3 min with stirring at 37°C (3 minutes incubation), or 
hirudin-anticoagulated blood was incubated for 10 min at 37°C without stirring, then diluted 1:1 with 
saline, and incubated for 3 min with stirring at 37°C (13 minutes incubation). Platelet stimuli were 
added thereafter. Results are expressed as mean values ± SD (n=5-12 with different blood donors). P 
values refer to paired two-sided t-test. 
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The additional pre-incubation period of blood at 37oC led to reduction of 
spontaneous aggregation (control) from 54 ± 16 to 34 ± 18 AU*min (P < 0.01, n=12 
with different donors) (Figure 3.2). 5-HT alone, as described above, did not induce 
platelet aggregation compared to control. The 10 min pre-incubation at 37oC also 
reduced the aggregation observed in the presence of 10 µM 5-HT from 58 ± 25 to 39 
± 19 AU*min (P < 0.05 n=9 with different donors) (Figure 3.11). The epinephrine-
induced platelet aggregation tended to be inhibited by the 10 min pre-incubation at 
37oC, but statistical significance was not reached (82 ± 34 to 72 ± 28 AU*min, P = 
0.09, n=8 with different donors) (Figure 3.11). The combined effect of 10 µM HT plus 
10 µM epinephrine was inhibited by 10 min pre-incubation at 37oC from 350 ± 134 to 
163 ± 76 AU*min (P < 0.01, n=8 with different donors) (Figure 3.11). 
The relatively high platelet aggregation induced by 5 µM ADP was also 
significantly decreased from 388 ± 101 to 247 ± 68 AU*min by 10 min pre-incubation 
at 37oC (P = 0.01, n=5 with different donors) (Figure 3.11). The same pre-incubation 
inhibited the moderate platelet aggregation induced by 1 µM ADP (261 ± 133 versus 
158 ± 93 AU*min for 3 and 13 minutes incubation respectively), but no statistical 
significance was reached (P = 0.14, n=5 with different donors) (Figure 3.11). 
Similarly, the high amount of platelet aggregation induced by 5 µM TRAP was 
significantly inhibited from 627 ± 96 to 325 ± 143 AU*min by 10 min pre-incubation 
at 37oC, while the inhibition of moderate platelet aggregation induced by 2 µM 
TRAP, from 128 ± 86 to 62 ± 36 AU*min, did not reach statistical significance (P = 
0.01 and P = 0.08 with 5 and 2 µM TRAP respectively, n=5 with different donors) 
(Figure 3.12). 
[54] 
 
In contrast, the 10 min pre-incubation at 37oC had no effect on the platelet 
aggregation induced by collagen and human plaque (P = 0.96 and P = 0.52 
respectively, n=5 with different donors) (Figure 3.12). 
 
Figure 3.12: Effect of different incubation periods at 37oC on TRAP-, collagen- and plaque-
induced platelet aggregation. Hirudin-anticoagulated blood was diluted 1:1 with saline, and 
incubated for 3 min with stirring at 37°C (3 minutes incubation), or hirudin-anticoagulated blood was 
incubated for 10 min at 37°C without stirring, then diluted 1:1 with saline, and incubated for 3 min 
with stirring at 37°C (13 minutes incubation). Platelet stimuli were added thereafter. Results are 
expressed as mean values ± SD (n=5-12 with different blood donors). P values refer to paired two-
sided t-test. 
 
In conclusion, pre-incubation of whole blood at 37oC for 10 minutes prior to the 
standard 3-min incubation in MEA, inhibited significantly the spontaneous 
aggregation, as well as the platelet aggregation observed after addition of 5-HT, 5-HT 
plus epinephrine, high concentrations of TRAP and ADP, and tended to inhibit the 
platelet aggregation induced by epinephrine and small concentrations of TRAP and 
ADP. All the receptors of the above stimuli, even of spontaneous aggregation which 
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is ADP-dependent, are coupled to G-proteins. On the other hand, whole blood 
platelet aggregation induced by collagen and atherosclerotic plaque, whose 
receptors are not G-protein coupled, were not affected by incubation of whole blood 
at 37oC for 10 minutes. 
3.2 Role of the platelet 5-HT2A receptor for platelet adhesion, 
aggregation and secretion in blood  
3.2.1 Role of 5-HT2A receptor antagonists on 5-HT induced potentiation of 
platelet aggregation 
The main 5-HT receptor on the platelet surface is the Gq-coupled 5-HT2A 
receptor (6). Since exogenously administered 5-HT can potentiate human whole 
blood platelet aggregation induced by a variety of agonists, we investigated the 
effect of 5-HT2A receptor antagonists on 5-HT-dependent aggregation. Once again, 
we used the model of 5-HT plus epinephrine-induced platelet aggregation, where 
the potentiating effect of 5-HT on the weak aggregation induced by epinephrine is 
quite pronounced. 
Three different 5-HT2A antagonists were used: ketanserin, R-96544 and 
sarpogrelate (112, 139, 140). The 5-HT-potentiated platelet aggregation was dose 
dependently inhibited to levels of 64 ± 42 and 76 ± 29 AU*min with 10 µM 
ketanserin and 10 µM R-96544, respectively, levels that are similar to the amount of 
aggregation induced by 10 µM epinephrine alone. Statistical significance was 
reached at concentrations of ≥ 10 nM for ketanserin and of ≥ 1nM for R-96544. The 
IC50 values of ketanserin and R-96544 hydrochloride were 5.6 and 1.8 nM, 
[56] 
 
respectively. Statistical significance of inhibition by sarpogrelate required a much 
higher concentration (100µM) (Figure 3.13). 
 
Figure 3.13: Effect of three different 5-HT2A receptor antagonists on 5-HT-dependent platelet 
aggregation in whole blood. Hirudin-anticoagulated blood was incubated with different 
concentrations of ketanserin, R-96544 and sarpogrelate for 3 min with stirring at 37°C before addition 
of 10 µM 5-HT plus 10 µM epinephrine. The platelet aggregation response was recorded by MEA for 5 
min. Aggregation induced by 5-HT plus epinephrine was set to 100% in individual experiments. Results 
are expressed as mean values ± SE (n=5 with different blood donors). 
 
3.2.2 Effect of ketanserin on stimulus-induced whole blood platelet aggregation 
After examining the effect of 5-HT2A antagonists on 5-HT-dependent platelet 
aggregation, we examined the effect of ketanserin on aggregation induced by 
physiological and pathophysiological platelet stimuli, such as collagen, TRAP and 
plaque. 
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In 5 experiments with different blood donors a supramaximal concentration of 1 
µM ketanserin inhibited potently the 5-HT-dependent platelet aggregation, but did 
not have any effect on platelet aggregation induced by collagen (0.1 µg/ml and 0.5 
µg/ml), plaque (0.42 mg/ml) and TRAP (5 µM) (Figure 3.14). 
 
 
Figure 3.14: Effect of ketanserin on stimulus-induced platelet aggregation in whole blood. 
Hirudin-anticoagulated blood was incubated in the absence or presence of 1 μM ketanserin for 3 min 
at 37°C before addition of 10 µM 5-HT plus 10 µM epinephrine, collagen (0.1 µg/ml and 0.5 µg/ml), 
plaque (0.42 mg/ml) or TRAP (5 µM). The platelet aggregation response was recorded by MEA for 5 
min. Results are expressed as mean values ± SD (n=5 with different blood donors). * P < 0.05  
 
3.2.3 Effect of ketanserin on stimulus-induced ATP secretion in whole blood 
Aside from the effects on platelet aggregation, we examined the effects of 
ketanserin on ATP secretion in the same blood donors. After platelet activation, ATP 
secretion originates from dense granules as 5-HT secretion does (33). 
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No ATP secretion was observed without addition of platelet stimuli (Figure 3.15). 
The small amount of ATP secretion observed in blood stimulated with 10 µM 5-HT 
plus 10 μM epinephrine (22 ± 21 nM, mean ± SD) was completely inhibited by 1 µM 
ketanserin (Figure 3.5). 
The low ATP secretion induced by 0.1 µM collagen was not inhibited by 1 µM 
ketanserin. At higher concentrations of collagen (0.5 µg/ml), an ATP secretion of 237 
± 135 nM ATP without ketanserin and 152 ± 80 nM ATP with ketanserin was 
observed, but the difference was not statistically significant (P=0.11, n=5) (Figure 
3.15). 
The plaque-induced ATP secretion reached 57 ± 29 nM ATP and the TRAP-
induced ATP-secretion reached 227 ± 215 nM ATP. Ketanserin did not inhibit ATP-
secretion induced by either human plaque or ATP (Figure 3.15).  
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Figure 3.15: Effect of ketanserin on stimulus-induced ATP secretion in whole blood.  Diluted hirudin-
anticoagulated blood (1:1) was incubated for 30 seconds with luciferin-luciferase reagent, then 1 µM 
ketanserin or solvent was added and blood was further incubated for 3 min at 37°C before addition of 
10 µM 5-HT plus 10 µM epinephrine, collagen (0.1 µg/ml and 0.5 µg/ml), plaque (0.42 mg/ml) or TRAP 
(5µM). The maximum ATP response was recorded by luminescence. Results are expressed as mean 
values ± SD (n=5 with different blood donors). * P < 0.05 for Mann–Whitney rank sum test. † Values 
are 0 ± 0 nM ATP (mean ± SD). 
 
 
In conclusion, ketanserin inhibited only the 5-HT-dependent ATP secretion, but 
not the ATP secretion induced by three important pathophysiological relevant 
platelet agonists, namely TRAP, collagen and plaque. 
 
3.2.4 Effect of ketanserin on plaque-induced platelet aggregate formation 
under arterial flow 
Ketanserin did not affect platelet aggregation and dense granule secretion after 
stimulation with various platelet stimuli in static assays. To explore our question in 
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under more relevant pathophysiological conditions we examined the effect of 
ketanserin under arterial flow conditions using human plaque-homogenate coated 
surfaces, a model that resembles in vivo atherothrombus formation. The shear rate 
applied was 500 s-1, which corresponds to blood flow in medium sized arteries. The 
platelet surface coverage was measured by fluorescence (Figure 3.16). 
A maximal concentration of ketanserin (1 µM) had neither at early, nor at late 
stages after start of blood flow, a significant effect on platelet adhesion and 
aggregation to human atherosclerotic plaques (Figure 3.17). Thus 5-HT2A receptor 
antagonism does not affect the plaque-induced platelet aggregation under flow. 
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Figure 3.16: Human plaque-induced platelet adhesion and aggregation under arterial flow with and 
without ketanserin. Fluorescence micrographs. Hirudin-anticoagulated blood was incubated for 3 
min at 37oC with solvent (control) or ketanserin (1 µM) along with 10 µM mepacrine to stain platelets.  
Blood was then perfused over plaque-coated surfaces for 10 min at 37
o
C at a shear rate of 500 s
-1
. 
Fluorescent images of one representative experiment at the start (0 min) and at the end (10 min) in 
the presence or absence of 1 µM ketanserin are shown. The light-green areas at 0 min are due to 
autofluorescence of the plaque material, while the brighter green areas at 10 min is fluorescence 
emitted from the mepacrine-stained platelets and platelet aggregates. 
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Figure 3.17: Effect of ketanserin on human plaque-induced platelet adhesion and aggregation 
under arterial flow. Line diagram. Blood was treated as in Fig. 3.16. Platelet coverage was quantified 
each minute. Values (% of platelet coverage of control at 10 min) are mean ± SD (n= 3 with different 
blood donors). 
 
3.2.5 Effect of 5-HT2A receptor antagonism on shear-induced platelet adhesion 
and aggregate formation 
We also examined the effect of ketanserin on shear-induced platelet adhesion 
and aggregation using a different experimental model, the cone and plate analyzer 
(137). Two different shear rates, 600 s-1 and 1200 s-1 were applied. The experiments 
at 1200 s-1 expanded the applicability of our findings at shear stress rates found in 
slightly stenotic arteries. 
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Figure 3.18: Shear stress-induced platelet adhesion and aggregate formation is not affected by 
ketanserin. Blood (0.25 mL) was incubated with solvent (control), ketanserin (1 µM) or R-96544 (1 
µM) for 3 min before application of two different shear rates for 2 min in a cone and plate analyzer. (i) 
Platelet surface coverage. (ii) Average size of platelet aggregates. Values are mean ± SD (n= 5 with 
different blood donors). 
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The two potent 5-HT2A receptor antagonists ketanserin and R-96544 did not 
inhibit shear stress induced platelet adhesion and aggregate formation, either at a 
shear rate of 600 s-1 or at a shear rate of 1200 s-1 (Figure 3.18). 
 
3.3 Role of the platelet 5-HT4 receptor for platelet aggregation in 
blood 
3.3.1 Role of 5-HT4 receptor agonism on platelet aggregation 
Recently the expression of 5-HT-4 receptors was described in human platelets 
(126). In two contradictive studies, a potent, partial 5-HT4 receptor agonist was 
found either to enhance or not to affect stimulus-induced platelet aggregation in 
PRP in vitro (126, 128). In view of these results, we investigated the effect of 5-HT4 
receptor activation on platelet function in blood by using multiple electrode 
aggregometry. 
A stimulation of a physiologically relevant Gs-coupled 5-HT4 receptor would 
theoretically raise the intracellular levels of cAMP leading to inhibition of platelet 
aggregation. We explored the effect of CJ-033,466, a potent and selective 5-HT4 
receptor agonist (141) on inhibition of platelet aggregation induced by ADP. 
However, pre-incubation of blood (3 min) with 5 different concentrations of CJ-
033,466 had no effect on platelet aggregation induced by two concentrations of ADP 
(1 µM and 5 µM) (Figure 3.19). 
Next, we examined the effect of 5-HT4 activation on spontaneous platelet 
aggregation, which is also dependent on ADP. This originates from erythrocytes 
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which are mechanically altered by the stirring process, and is released to the 
extracellular space (142). As in the experiments of ADP-induced aggregation, CJ-
033,466 had no effect on spontaneous aggregation (Figure 3.20, lower curve).  
 
 
Figure 3.19: Effect of 5-HT4 activation on ADP-induced platelet aggregation in whole blood. 
Hirudin-anticoagulated blood was incubated with different concentrations of CJ-033,466 for 3 min 
with stirring at 37°C before addition of two different concentrations of ADP. Results are expressed as 
mean +SD (n=5 with different blood donors). 
 
Last, we examined the effect of 5-HT4 activation on the small increase of 
aggregation induced by epinephrine, which activates platelets through an α2-
adrenergic receptor coupled Gi-mediated pathway (51). If active 5-HT4 receptors 
coupled to Gs existed on the platelet surface, CJ-033,466 would directly counteract 
epinephrine’s weak platelet stimulatory action. Indeed, CJ-033,466 dose-
dependently reduced the epinephrine-induced aggregation. It was significant at 1 
and 10 µM concentrations of CJ-033,466, respectively (P < 0.05, n=6 with different 
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blood donors) (Figure 3.20, upper curve). This indicates that active 5-HT4 receptors 
may exist on the platelet membrane surface. 
 
 
Figure 3.20: Effect of 5-HT4 activation on spontaneous and epinephrine-induced platelet 
aggregation in whole blood. Hirudin-anticoagulated blood was incubated with different 
concentrations of CJ-033,466 for 3 min with stirring at 37°C before addition of 10 µM epinephrine or 
solvent. Results are expressed as mean values + SD (n=6 and n=7 with different blood donors for 
epinephrine-induced and spontaneous aggregation respectively). * P < 0.05 for paired two sided t test 
versus control (0 nM CJ-033,466). 
 
3.3.2 Role of 5-HT4 receptor antagonism on platelet aggregation 
Furthermore, the role of 5-HT4 receptor antagonism was examined using two 
potent and selective structurally distinct 5-HT4 receptor inhibitors, GR113808 and RS 
23597-190 (143, 144). 
If 5-HT activated both a stimulatory 5-HT2A receptor and an inhibitory 5-HT4 
receptor on platelets, the inhibition of active 5-HT4 receptors on the platelet surface 
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would blunt the 5-HT4-mediated increase of intracellular cAMP and potentiate 5-HT-
dependent platelet aggregation induced by 5-HT alone (via the Gq-dependent 5-
HT2A pathway) or in combination with epinephrine (activation of the Gi pathway). 
However, incubation of blood with 5 different concentrations of the two 5-HT4 
receptor antagonists GR113808 and RS 23597-190 did not have any effect on whole 
blood platelet aggregation induced by 10 µM 5-HT alone or in combination with 10 
µM epinephrine (Figure 3.21). Hence 5-HT does not activate the platelet 5-HT4 
receptor in blood. 
[68] 
 
 
Figure 3.21: Effect of 5-HT4 antagonism on 5-HT-dependent platelet aggregation in whole 
blood. Hirudin-anticoagulated blood was incubated with different concentrations of GR113808 (i) and 
RS 23597-190 (ii) for 3 min with stirring at 37°C before addition of 10 µM 5-HT alone or 10 µM 5-HT 
plus 10 µM epinephrine. Results are expressed as mean values ± SD (n=5 with different blood donors). 
 
 
 
0
50
100
150
200
250
300
350
400
450
0 nM 1 nM 10 nM 100 nM 1 µM 10 µM 
A
gg
re
ga
ti
o
n
, A
U
*m
in
[ GR113808 ]
5-HT 10 µM
5-HT 10 µM + Epinephrine 10µM
i
0
100
200
300
400
500
600
0 nM 1 nM 10 nM 100 nM 1 µM 10 µM 
A
gg
re
ga
ti
o
n
, A
U
*
m
in
[ RS 23597-190 ] 
5-HT 10 µM
5-HT 10 µM + Epinephrine 10µM
ii
[69] 
 
4. Discussion 
4.1 Role of exogenous 5-HT on whole blood platelet aggregation 
We found that 5-HT on its own did not induce platelet aggregation in blood. We 
hypothesized that 5-HT released from some platelets activated during venipuncture 
might cause homologous desensitization of the 5-HT receptor(s) and therefore, a 
platelet response to 5HT might not be detectable, if measured 30 min after 
venipuncture. Platelets might respond to 5-HT very early after venipuncture, where 
receptor desensitization might not yet have occurred. Therefore, we measured 5-HT 
induced platelet aggregation as early as 5 min after venipuncture and compared the 
values with the aggregation values obtained 15 and 30 minutes after venipuncture. 
However, no 5-HT-induced aggregation was observed in these experiments either. 
Our results do not agree with Bevan et al. who showed a small reversible 
proaggregatory effect of 5-HT by measuring the decrease of platelet count in whole 
blood (105). Our observations, however, confirm the results of Li et al. who 
measured 5-HT-induced platelet aggregation in blood by using impedance 
aggregometry, the decrease in platelet count and in vitro filtragometry (the time 
taken for platelet aggregates to occlude a microfilter), and who observed no 
platelet-stimulating effect of 5-HT alone on platelets in whole blood (106).  
In contrast, 5-HT is known to potentiate platelet aggregation in blood induced by 
thrombin, ADP, epinephrine, lysophosphatidic acid (LPA) and collagen (106, 145-
147). Usually pairs of platelet stimuli with different signaling mechanisms show good 
potentiation. For example 5-HT, whose platelet 5-HT2A receptor is coupled to Gq 
proteins and ultimately activates PKC and mobilizes Ca++ (145, 146), synergizes well 
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in PRP  with epinephrine, which decreases intracellular cAMP through Gi-coupled α2-
adrenergic receptors (147). This potentiation of epinephrine-induced aggregation by 
5-HT was confirmed in our experiments in whole blood.  Data from Shah et al in PRP 
show that the synergism of 5-HT plus epinephrine can be inhibited at different steps 
of the 5-HT- or epinephrine-dependent signaling cascades (147). On the other hand, 
5-HT cannot potentiate platelet aggregation induced by ATP, whose main 
mechanism is the same as 5-HT, the mobilization of Ca++ (148). The synergism of 5-HT 
with LPA is dependent on dense granule secretion of ADP, which binds to a Gi-
coupled P2Y12 receptor (probably the synergizing receptor) and to a P2Y1 receptor 
which couples to Gq as 5-HT does. (146). Yet, not all different aggregation signaling 
pathways potentiate each other: the synergism of 5-HT with collagen (145) does not 
seem to depend on the collagen-induced GPVI/tyrosine kinase signaling cascade 
(149), but rather seems to be mediated by the ADP- or thromboxane A2-pathways, 
which are activated in collagen-induced platelet activation (146, 149).  
4.2 Role of the platelet 5-HT transporter for platelet aggregation 
In order to shed light on the possible role of SERT for platelet activation, we 
conducted in vitro experiments with the SSRI fluoxetine in whole blood. The SSRIs 
are nowadays the most commonly prescribed antidepressant drugs (89). They have 
been shown to deplete 5-HT from the platelets’ dense granules (84, 85). 
Nevertheless, the implications of the SSRI pharmacotherapy for the platelet 
aggregation response are unclear.  
The results demonstrated that fluoxetine inhibited the 5-HT (10 µM)-dependent 
potentiation of epinephrine-induced aggregation. The effects were shown in 3 
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different sets of experiments with 3 different pre-incubation periods of fluoxetine (5 
sec, 3min and 13 min). The degree of inhibition did not differ significantly between 
these 3 sets. Dose-inhibition curves showed IC50 values of 10-20 µM fluoxetine which 
are in the range of the highest blood concentrations of fluoxetine (about 10 µM)  
reported after clinical administration (138). If the synergistic effect of 5-HT were 
important for the in vivo platelet aggregation, clinically administered fluoxetine 
should provide cardioprotective effects. 
Fluoxetine had no effect on the platelet aggregation induced by platelet stimuli 
which activate GPCRs (ADP or TRAP). Furthermore, no inhibition of platelet 
aggregation by fluoxetine was observed with collagen and human plaque, which 
activate glycoprotein VI (GPVI) (36, 131). Our results clearly indicate that fluoxetine 
in blood does not impair the platelet aggregation process itself, as it has recently 
been suggested based on the observed interaction of SERT with the integrin αIIbβ3 at 
the platelet surface (78). Furthermore, fluoxetine does not impair GPVI and G-
protein dependent pathways of platelet aggregation. 
Our results indicate that fluoxetine only inhibits the potentiation of platelet 
aggregation mediated by addition of exogenous 5-HT to blood. A possible 
explanation is that fluoxetine inhibits the 5-HT induced platelet activation of the 5-
HT2A receptor. Since the SSRI fluoxetine has an appreciable affinity for 5-HT2A 
receptors (150, 151), and 5-HT2A receptors are solely responsible for the synergistic 
effect of exogenously administered 5-HT on platelet aggregation, the anti-
aggregatory effect of fluoxetine on 5-HT-potentiated platelet aggregation can be 
attributed to the blockade of 5-HT2A receptors. Our findings regarding the fact that 
fluoxetine pre-incubation of 5 sec, 3 min or 13 min has a similar inhibitory effect on 
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platelets stimulated by 5-HT plus epinephrine also supports that fluoxetine inhibits 
platelet aggregation by antagonizing the 5-HT2A receptors. 
Moreover our findings show that fluoxetine did not attenuate non-5-HT-
dependent platelet aggregation. This result indicates that protein serotonylation 
mediated by released 5-HT which is re-taken up by SERT, is not involved in platelet 
activation induced by physiological platelet stimuli.  
Another  previously proposed mechanism of 5-HT dependent platelet activation 
is the covalent binding of 5-HT to fibrinogen and thrombospondin on COAT-platelets, 
a subpopulation of platelets which express on their surface a variety of α-granule 
proteins in a stable manner (see Introduction 1.7) (99-101). If COAT-platelets were 
formed in our experiments and played a pro-aggregatory role as proposed (99-101), 
an acute blockade of 5-HT uptake activity by fluoxetine leading to a local high 
extracellular concentration of 5-HT should have resulted in a higher percentage of 
COAT-platelets and higher platelet aggregation values. Such an effect was, however, 
not observed in our experiments. Thus, we conclude that either no COAT-platelets 
were produced or that their existence did not affect platelet aggregation. We should, 
nevertheless, mention that the stimuli used in our experiments were rather weak in 
comparison to the combination of strong stimuli (e.g. collagen plus thrombin) 
previously used to produce COAT-platelets (99-101).  
Our findings do not confirm a previous in vitro study showing augmentation of 
PAR-1- or PAR-4-induced platelet aggregation by fluoxetine (98). They are also in 
contrast to two other in vitro studies, which used washed platelets and showed 
inhibition of ADP-induced aggregation and collagen-mediated platelet activation and 
aggregation by the SSRI citalopram (78, 152). Our results are in agreement with an in 
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vitro study in PRP showing inhibition of 5-HT-enhancement of ADP-induced 
aggregation by citalopram (97). As far as clinical studies are concerned, our results 
do not support two studies reporting increased cardiovascular risk after initiation of 
SSRI treatment in elderly (95, 96). In contrast, our findings might lend some indirect 
support of epidemiological studies showing increased bleeding tendency and 
protection against cardiovascular disease under SSRI treatment (86-88, 91-93). This 
effect could be more pronounced with concomitant use of NSAIDs or aspirin, which 
inhibit a different pathway, the cyclooxygenase-dependent aggregation pathway. To 
examine this possibility, we studied next the combined effect of aspirin and 
fluoxetine on platelet aggregation in vitro in whole blood.  
4.3 Effect of the combination of fluoxetine plus acetylsalicylic acid 
on inhibition of platelet aggregation 
Two epidemiological studies have reported an increased risk of upper 
gastrointestinal bleeding in patients receiving SSRIs in combination with NSAIDs or 
aspirin (86, 89). Another study, however, failed to demonstrate platelet inhibition ex 
vivo in patients treated with a SSRI plus aspirin (153).  
We therefore examined the possible synergistic action of SSRIs and aspirin on the 
pathophysiological relevant plaque-induced platelet aggregation and on the 5-HT-
dependent platelet aggregation (5-HT + epinephrine) in whole blood in vitro. Similar 
to our previous findings, fluoxetine inhibited potently the 5-HT-dependent, but not 
the plaque-induced platelet aggregation. On the contrary, aspirin inhibited potently 
the plaque-induced, but not the 5-HT-dependent platelet aggregation. Neither the 
inhibition of 5-HT-dependent platelet aggregation, nor the inhibition of plaque-
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induced aggregation by aspirin was increased by the combination of aspirin and 
fluoxetine. Therefore, we conclude that it is not the combined effects of SSRIs and 
aspirin on platelet aggregation that can be held responsible for bleeding 
complications. 
Interestingly, a recent study has shown that SSRIs are associated with 
uncomplicated peptic ulcers (154). A previous study in mice had also shown that 
injected 5-HT aggravates peptic ulcers in mice, probably by damaging the 
regenerative microvessels involved in the healing process of these ulcers (155). A 
transient increase of plasma 5-HT by some monoamine transporter inhibitors has 
also been shown (156).  Hence, the combination of attenuated platelet aggregation 
by aspirin and NSAIDs with an aggravation of peptic ulcers by increased free plasma 
5-HT under SSRI treatment could be a possible explanation of an increased upper 
gastrointestinal bleeding risk, but further studies are needed.  
4.4 Role of blood pre-incubation on stimulus-induced platelet 
aggregation 
During our experiments with fluoxetine we also observed that both platelet 
aggregation induced by ADP, TRAP, epinephrine, 5-HT plus epinephrine, which act on 
G-protein coupled receptors, and the spontaneous platelet aggregation, which is 
ADP-dependent (157), were lower, when blood was pre-incubated for 10 min at 37°C 
compared to 0 min pre-incubation time. In contrast, platelet aggregation induced by 
collagen and atherosclerotic plaque, which do not activate GPCRs were not affected 
by the additional 10 min incubation at 37oC.  
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Although there is no simple explanation for these results, I would like to 
comment that these findings are in accordance with previous findings that show 
lower affinity of G-protein coupled receptor for their ligands at temperatures ranging 
from 37o to 50oC compared to room temperatures (158-161), and with a previous 
study that showed enhanced platelet aggregation and activation at 28oC, a 
temperature attained during hypothermia in cardiac surgery (162). 
4.5 Role of the platelet 5-HT2A receptor for platelet activation 
under static and flow conditions 
The next step in our research concerned the role of 5-HT2A receptors on platelet 
aggregation. Until now, human and animal studies have shown unequivocally that 
antagonism of the 5-HT2A receptors attenuates platelet aggregation mediated by 
exogenous 5-HT in vitro and ex vivo (106, 108-112, 114, 115). 
We ran a set of experiments examining the effect of different concentrations of 
three 5-HT2A receptor antagonists (ketanserin, R-96544 and sarpogrelate) on 5-HT-
dependent platelet aggregation in whole blood. Platelet aggregation induced by 
epinephrine plus 5-HT was potently inhibited by ketanserin and R-96544. 
Sarpogrelate, on the other hand, required much higher concentrations to inhibit 5-
HT-potentiated platelet aggregation. Moreover, high concentrations of 10 µM of 
ketanserin and 10 µM R-96544 inhibited platelet aggregation to levels of 64 ± 42 and 
76 ± 29 AU*min, which are similar to levels induced by epinephrine alone. In 
additional experiments on ATP secretion, the little amount of ATP secretion induced 
by epinephrine plus 5-HT was completely inhibited by 1 µM ketanserin. 
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According to these results, a potent blockade of 5-HT2A antagonists leads to 
complete inhibition of 5-HT-dependent platelet aggregation. Finally, we can infer 
that the 5-HT2A receptors are solely responsible for the potentiation of platelet 
aggregation by exogenously administered 5-HT.  
Moreover, the complete inhibition of 5-HT-potentiated platelet aggregation by 
the 5-HT2A receptor antagonist, discards the possibility that serotonylation of 
cytoplasmic proteins plays any role in platelet activation, since according to Walther 
et al added 5-HT would enhance platelet activation through SERT mediated cytosolic 
5-HT increase and subsequent protein serotonylation (102). 
The next step was to investigate the role of endogenous 5-HT in stimulus-induced 
platelet aggregation. The various concentrations of endogenous 5-HT in human 
blood compartments are as follows: The 5-HT concentration of platelet depleted 
plasma is very low, and ranges between 10 and 44 nM (163-166). Platelet 5-HT 
(measured in PRP) is between 3.22 and 6 nmol/109 platelets (164, 165, 167, 168). In 
the hypothetical scenario of complete exocytosis of platelet 5-HT, an individual with 
a high platelet count (400.000/μl) and the maximum platelet 5-HT concentration (6 
nmol/109 platelets), could reach a maximal blood 5-HT concentration of 2.4 μΜ after 
platelet stimulation. According to another study the average total 5-HT content of 
blood (including platelets) is 0.74 µM (169). Since 5-HT is not completely released 
even after stimulation with a strong platelet stimulus such as collagen (170), the 
extracellular 5-HT blood concentration is expected to be lower than 0.74 µM. This 
level of 5-HT concentration is much lower than the 10 µM 5-HT used for potentiation 
of platelet aggregation in our experiments. However, in a previous study using 
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human PRP a 5-HT concentration as low as 0.5 µΜ could potentiate ADP-induced 
aggregation (171). 
Our next aim was to study the possible role of released 5-HT as a feedback 
mediator of human platelet activation. In order to reach a solid, reliable conclusion 
we assessed the effect of 5-HT2A receptor antagonism in four different types of 
experiments using whole blood; namely MEA, platelet ATP secretion, plaque-induced 
platelet adhesion and aggregation under arterial flow conditions, and shear-induced 
platelet adhesion and aggregate formation.  
We found that a supramaximal concentration of 1 µM ketanserin had no effect 
on platelet aggregation induced by collagen, TRAP and plaque measured by MEA. 
Similarly, ketanserin did not inhibit platelet ATP secretion induced by the same 
platelet agonists. Ketanserin had also no effect on human plaque-induced platelet 
adhesion and aggregation under arterial flow. Moreover, neither ketanserin nor R-
96544 affected platelet adhesion and aggregate formation induced by two different 
shear rates, 600 s-1 and 1200 s-1 as measured by the cone and plate analyzer (137). 
These results demonstrate clearly that endogenous serotonin released upon platelet 
stimulation does not support platelet aggregation and secretion. Our experiments on 
platelet adhesion and aggregate formation stimulated by different shear rates and 
by atherosclerotic plaque under arterial flow conditions extend the applicability of 
our findings to pathophysiological situations of rupture of atherosclerotic plaques in 
normal sized and stenotic arteries. Our findings are in contrast to several studies 
performed in dogs that reported, in the absence of exogenous serotonin, an 
inhibition of stimulus-induced platelet aggregation by 5-HT2A receptor antagonists 
in vitro, ex vivo and in vivo (118-120). Also, in other species, inhibition of stimulus-
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induced platelet aggregation by 5-HT2A receptor antagonists has been observed in 
the absence of added serotonin (112, 114, 117, 172). In animal in vivo thrombosis 
models the effect 5-HT2A antagonists on platelets and VSMCs (vasoconstriction) 
cannot be separated. In these models the inhibition of vasoconstriction induced by 
5-HT, and not attenuated platelet aggregation, might be the reason, why 5-HT2A 
receptor antagonism is effective in thrombosis models. 
Thus, it seems that in species other than human, serotonin released upon 
platelet stimulation might serve as positive feedback mediator of platelet activation. 
Why it does not have this function in human platelets is intriguing. It could be that 
the amount of serotonin released from human platelets is not sufficient to activate 
the human platelet 5-HT2A receptor. The theoretical maximum extracellular 5-HT 
concentration in human blood, as calculated above is 2.4 μΜ, whilst in an in vivo 
experiment in dogs, the maximum 5-HT plasma concentration in the vicinity of a 
coronary occlusion measured was approximately 2.3 μΜ (173). According to these 
results, there is no substantial difference between the 5-HT concentrations in men 
and dogs that could explain the difference in the potentiation of aggregation by 
secreted 5-HT. 
A second possibility is that 5-HT released from stimulated platelets does not 
reach its 5-HT2A receptor, perhaps since it is taken up before by SERT. The blockade 
of SERT should then enhance stimulus-induced aggregation. However, the results of 
our experiments do not support this suggestion: fluoxetine did not enhance 
aggregation induced by epinephrine, ADP, TRAP, plaque and collagen.  
A third possibility is a different structure and pharmacology of 5-HT2A receptors 
of humans as compared to other species (174, 175). Human, monkey and pig 5-HT2A 
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receptors have a higher affinity for tryptamines without N1-substitution than rat 5-
HT2A receptors (174-176); thus human 5-HT2A receptors should have had a greater 
affinity for 5-HT, a N1-unsubstituted tryptamine, and enhanced platelet response to 
5-HT as compared to rats. However, 5-HT2A blockade inhibited collagen-induced 
platelet aggregation in rats and not men (117, 177). Thus, it is not the different 
affinity to the 5-HT2A receptor that enables rat platelets to respond to endogenously 
released 5-HT. The reason behind the difference of human platelets and the platelets 
from other species (mice, rats, cats, dogs) concerning their response to 
endogenously released 5-HT, might be sought in the signaling activity of the 5-HT2A 
receptor. If the porcine or monkey platelet response to 5-HT was similar to that of 
human platelets, they would provide a better animal model for future research. 
The findings of this study lead to the conclusion that 5-HT2A receptor 
antagonists do not provide a promising strategy for antiplatelet therapy. Our findings 
also suggest that inhibition of platelet aggregation will not be a side effect of 5-HT-
related medications that target other organ systems. 
4.6 Role of the platelet 5-HT4 receptor for platelet aggregation 
The expression of 5-HT-4 receptors (serotonin type 4 receptors) has been 
recently described in human platelets (126). The 5-HT4 receptors are Gs-coupled 
receptors and, therefore, their activation would theoretically lead to inhibition of 
platelet activation. The opposite was demonstrated in a study, where tegaserod, a 5-
HT4 receptor agonist, enhanced platelet aggregation induced by other stimuli in PRP 
(126). Yet, in another study tegaserod did not alter ADP-induced platelet aggregation 
in PRP (128). 
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Our results were the first that used whole blood to test the effect of 5-HT4 
receptor agonists and antagonists on platelet aggregation. They show that the 
stimulation of platelet 5-HT4 receptors by a wide range of 5-HT4 agonist (CJ 033,466) 
concentrations had no effect on whole blood platelet aggregation. Moreover, 5-HT4 
agonism had no effect on spontaneous platelet aggregation. Nevertheless, 1 µM and 
10 µM CJ 033,466 inhibited significantly the weak platelet aggregation induced by 
epinephrine. We then moved on to examine the effects of 5-HT4 receptor 
antagonism. Incubation with five different concentrations of two structurally 
different 5-HT4 antagonists, GR113808 and RS 23597-190, did not affect whole 
blood platelet aggregation observed in the presence of 10 µM 5-HT or induced by 10 
µM 5-HT and 10 µM epinephrine.  
Since 5-HT4 antagonists did not enhance platelet aggregation in the presence of 
exogenous 5-HT, we cannot attribute the lack of effect by exogenous 5-HT alone on 
human platelet aggregation to a possible co-existence of two antagonizing receptors, 
5-HT2A and 5-HT4, on the platelet surface. We, therefore, conclude that 5-HT4 
receptors have no role on 5-HT-dependent platelet aggregation. 
We found that stimulation of 5-HT4 platelet receptors did not inhibit 
spontaneous platelet aggregation and aggregation induced by the ADP, however 5-
HT4 stimulation inhibited the small platelet aggregation induced by epinephrine. We 
should keep in mind that epinephrine receptors and 5-HT4 receptors antagonize 
each other on the cAMP intracellular pathway, by lowering and raising the 
intracellular cAMP concentrations respectively. The effect of 5-HT4 receptor agonism 
on epinephrine-induced aggregation is an indication that 5-HT4 receptors exist on 
the platelet surface. However, the effect of 5-HT4 receptors may be so weak that 
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their potential can be demonstrated only in special conditions, i.e. in the presence of 
weak platelet aggregation that depends on the cAMP-dependent pathway, as that 
induced by epinephrine. Therefore, we can conclude that platelet 5-HT4 receptors 
are of minor importance for platelet aggregation and do not constitute a notable 
target for antiplatelet drugs. 
4.7 Roles of platelet 5-HT in various diseases  
The roles of platelet 5-HT in various diseases are constantly being unraveled. 
Platelet-derived 5-HT plays a role in autoimmune disorders. Decreased contents 
of platelet 5-HT, possibly released during inflammatory episodes, have been found in 
patients with rheumatoid arthritis, systemic lupus erythematosus, progressive 
systemic sclerosis and Sjögren’s syndrome (15, 16, 178). In a mouse model of 
autoimmune arthritis platelet 5-HT has been implicated in joint inflammation by 
enhancing the permeability of the synovial microvasculature, an action antagonized 
by SSRIs (178). Similarly, a microvascular leak mechanism has been implicated in the 
aggravation of acute lung injury by platelet 5-HT (179). In addition, platelet-secreted 
5-HT promotes the recruitment of neutrophils to sites of acute inflammation (14), 
where it activates inflammatory signaling pathways (180). 
Platelet 5-HT has been reported to be important for liver regeneration after liver 
resection in rats and humans (12, 17, 181). However, platelet 5-HT is also involved in 
pathological conditions of the liver, such as liver fibrosis, steatohepatitis, liver 
carcinomas and aggravation of viral hepatitis (17-19). 
Administration of the drug tianeptine, an antidepressive agent, has been shown 
to enhance the uptake of plasma 5-HT by platelets and to diminish asthma attacks 
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(20). Platelet- derived 5-HT has further been shown to enhance migration of rat 
aortic smooth muscle cells, a function which might affect atherosclerosis (182). 
A recent study showed that elevated plasma 5-HT altered the expression of 723 
murine genes, which must reflect a wide range of 5-HT mediated functions (183). As 
mentioned in the introduction, a wide variety of 5-HT mediated functions exist, yet 
only the experiments mentioned above refer to the effects of 5-HT originating from 
platelets. Summing up, platelets serve as an important carrier of peripheral 5-HT and 
may distribute it upon demand to injured or inflamed organs and tissues.  
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5. Conclusion and perspectives 
 
Exogenous 5-HT potentiates platelet aggregation and this potentiation can be 
unequivocally inhibited by 5-HT2A receptor antagonists in many mammalian species, 
including man (109, 110, 112-116). In the absence of exogenous 5-HT, 5-HT2A 
antagonism also inhibits platelet activation in mice, rats, cats, rabbits and dogs (107, 
113, 114, 116-120). Therefore, 5-HT2A antagonists have been considered as possible 
anti-platelet drugs, although 5-HT2A antagonists have until now failed to inhibit 
platelet aggregation in vitro and ex vivo in man (107, 121-123).  
Our results show that 5-HT2A receptors mediate in blood the potentiation of 
human platelet aggregation by exogenous 5-HT (177), but they are not involved in 
the response of endogenously 5-HT released upon platelet activation by 
physiological stimuli, shear stress or by flow over plaque-coated surfaces (177). 
Hence, endogenous 5-HT does not play a role in human platelet aggregation.  
SSRIs on the other hand, have been held responsible for bleeding complications 
and protection from myocardial ischemia (86-93), effects which have not been 
confirmed by a few other studies (94-96). In our experiments the acute 
administration of the SSRI fluoxetine, alone or in combination with aspirin, did not 
inhibit platelet aggregation induced by physiological stimuli (157) and therefore, we 
conclude that fluoxetine does not interfere with physiological platelet aggregation 
mechanisms. Nevertheless, SSRIs could enhance bleeding complication by decreasing 
platelet 5-HT content leading to a reduced 5-HT mediated vasoconstriction or 
interference with the 5-HT mediated healing of peptic ulcers (2, 90, 154, 155). Our 
experiments showing that fluoxetine inhibits stimulus-induced platelet aggregation 
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in the presence but not absence of exogenous 5-HT (177), leave no room to support 
serotonylation of cytoplasmic or platelet surface proteins as a pro-aggregative 
mechanism (99-102). Additionally, we provide functional evidence for the presence 
of recently proposed platelet inhibitory 5-HT4 receptors (126, 128) on platelets, but 
they may play only a minor role in regulating human platelet aggregation. 
 The reason why platelet 5-HT plays a role in mice-, rat-, cat-, rabbit- and dog-, 
but not human platelet aggregation is intriguing and cannot be explained based on 
our current knowledge. The higher affinity for 5-HT of the human, monkey and 
porcine 5-HT2A receptor compared to that of the rat (174-176), does not explain the 
pro-aggregative effect of 5-HT in mice; but it suggests structural differences in the 5-
HT2A between species.  
Based on the current knowledge and on our study, we can conclude that platelet 
function is not affected by endogenous 5-HT, but platelets are important by serving 
as a carrier for 5-HT which is distributed to diseased organs and tissues. The absence 
of platelet pro-aggregative effects by endogenous 5-HT may prohibit the use of 5-
HT2A receptor antagonists as antiplatelet drugs, but it may also suggest a reduced 
adverse events profile for drugs targeting the platelet 5-HT uptake. Such drugs could 
be helpful for treatment of disorders that depend on platelet-derived 5-HT, like 
autoimmune disorders, liver diseases and asthma (12, 14-20, 178-181) and further 
platelet 5-HT-dependent disorders whose discovery is anticipated in the future.  
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6. Summary 
 
6.1 Summary 
The field of serotonin (5-HT) research continues to expand. A variety of 
physiological and pathophysiological functions regulated by 5-HT has been 
identified. Selective serotonin reuptake inhibitors (SSRIs) and 5-HT-3-receptor 
antagonists are used in medical therapy, and more 5-HT-related medicaments are 
expected in the future.  
Circulating 5-HT is stored mainly in the dense granules of platelets. 5-HT 
stimulates platelets, which has been observed, apart from humans, in various other 
species. Therefore, the stimulatory effect of exogenous 5-HT in high concentrations 
(> 0.5 μM) on human platelets in blood is unambiguous. However, results of the 
platelet-stimulating effect of the endogenous 5-HT, which is stored in dense granules 
and released upon platelet activation, are contradictory. 
The aim of this thesis was to investigate the acute effect of SSRIs on human 
platelet aggregation, the role of the 5-HT2A receptor for platelet function in human 
blood, and the role of the newly discovered 5-HT4 receptor for platelet function. 
 In some—but not all—clinical studies, SSRIs on the one hand have been 
suspected to cause bleeding complications, on the other hand they may protect 
against ischemic cardiovascular diseases. In our studies, the acute addition of the 
SSRI fluoxetine to blood, alone or in combination with aspirin, indeed inhibited the 
potentiation of platelet aggregation by exogenous 5-HT (probably by unspecific 
inhibition of 5-HT2A receptors), the platelet aggregation induced by physiological 
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stimuli was, however, not affected. Therefore, we conclude that the serotonin 
transporter is not involved in the physiological platelet aggregation process. Yet, 
SSRIs could cause bleeding complications by reducing the platelet 5-HT content, 
consequently leading to a reduced 5-HT-mediated vasoconstriction, or contribute to 
stomach ulcers by disruption of the 5-HT-mediated wound healing. 
Our results indicate that 5-HT2A receptors mediate the potentiation of 
aggregation of human platelets in the blood by exogenous 5-HT. However, 5-HT2A 
receptor antagonists do not inhibit platelet activation by physiological stimuli, shear 
stress, or flow over atherosclerotic plaque material. Therefore, endogenous 5-HT, 
which is released upon platelet activation, plays no role in human platelet 
aggregation. 
Finally, our studies support the expression of platelet-inhibiting 5-HT4 receptors. 
However, these played only a minor role in the regulation of human platelet 
aggregation induced by epinephrine. 
The question why platelet 5-HT plays a role in platelet aggregation of mice, rats, 
cats, rabbits, and dogs, but not of men, is intriguing, but has no explanation 
according to our present knowledge. Species-specific structural differences of the 5-
HT2A receptors are suggested. 
Based on the current knowledge and our experiments, it can be concluded that 
human platelet function is not influenced by endogenous 5-HT, but platelets are 
important for transporting 5-HT in the blood to diseased organs and tissues. The 
absence of a stimulating action of endogenous 5-HT on platelets precludes the use of 
5-HT2A receptor antagonists as anti-thrombotic medications. 
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6.2 Zusammenfassung 
Der Bereich der Serotonin- (5HT-) Forschung erweitert sich ständig. Eine Vielzahl 
von physiologischen und pathophysiologischen Funktionen, die durch 5-HT reguliert 
werden, wurde identifiziert. Selektive Serotonin-Wiederaufnahmehemmer (SSRIs) 
und 5-HT3-Rezeptor-Antagonisten werden in der medizinischen Therapie 
angewendet, und zukünftig könnten weitere 5-HT-bezogene Medikamente 
dazukommen. 
Zirkulierendes 5-HT ist vor allem in den dichten Granula von Thrombozyten 
gespeichert. Es stimuliert Thrombozyten von Menschen als auch von verschiedenen 
Tierspezies. Dabei ist die stimulierende Wirkung von exogenem 5-HT in hoher 
Konzentration ( > 0,5 µM) auf humane Thrombozyten eindeutig. Jedoch sind die 
Ergebnisse bezüglich der Thrombozyten-stimulierenden Wirkung des endogenen, in 
dichten Granula gespeicherten 5-HT, welches nach Thrombozytenaktivierung 
freigesetzt wird, widersprüchlich. 
Das Ziel der vorliegenden Arbeit war es, die akute Wirkung von SSRIs auf die 
Aggregation humaner Thrombozyten, und die Rolle des 5-HT2A-Rezeptor für die 
Thrombozytenfunktion im menschlichen Blut in vitro zu untersuchen, sowie die Rolle 
des 5-HT4-Rezeptors, eines neu-entdeckten Thrombozytenrezeptors, für die 
Plättchenfunktion zu erforschen. 
 SSRIs wurden aufgrund mancher, aber nicht aller klinischer Studien einerseits für 
Blutungskomplikationen verantwortlich gemacht, andererseits könnten sie bei 
ischämischen kardiovaskulären Erkrankungen protektiv wirken. In unseren 
Untersuchungen wurde durch die kurzfristige Zugabe des SSRI Fluoxetin zu Blut die  
Potenzierung der Thrombozytenaggregation durch exogenes 5-HT zwar gehemmt 
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(wahrscheinlich durch unspezifische Inhibierung des 5-HT2A-Rezeptors), die durch 
physiologische Stimuli induzierte Thrombozytenaggregation jedoch nicht beeinflußt. 
Daher folgern wir, dass thrombozytäre Serotonin-Transporter bei der 
physiologischen Thrombozytenaggregation nicht involviert sind. Dennoch könnten 
SSRIs zu Blutungskomplikationen führen (durch Verringerung des thrombozytären 5-
HT-Gehalts, und in Folge einer reduzierten 5-HT-vermittelten Vasokonstriktion), oder 
zu Magengeschwüren durch Störung der 5-HT-vermittelten Wundheilung beitragen.  
Unsere Ergebnisse zeigen, dass 5-HT2A-Rezeptoren die Potenzierung der 
Aggregation humaner Thrombozyten im Blut durch exogenes 5-HT vermitteln. 
Antagonisten des 5-HT2A-Rezeptors hemmen aber nicht die Thrombozyten-
Aktivierung induziert durch physiologische Stimuli, Scherstress oder Fluss über 
atherosklerotisches Plaquematerial. Endogenes 5-HT welches nach Thrombozyten-
Aktivierung freigesetzt wird, spielt daher keine Rolle in der menschlichen 
Thrombozytenaggregation. 
Zuletzt unterstützen unsere Untersuchungen die Expression von Thrombozyten-
Aggregationshemmenden 5-HT4 Rezeptoren. Diese spielten jedoch nur eine geringe 
Rolle bei der Regulation der Adrenalin-induzierten Thrombozytenaggregation. 
Die Frage, warum thrombozytäres 5-HT zwar eine Rolle bei der 
Thrombozytenaggregation von Mäusen, Ratten, Katzen, Kaninchen und Hunden, 
aber nicht bei der humanen Thrombozytenaggregation spielt, ist fesselnd, aber lässt 
sich gemäß unseren derzeitigen Kenntnissen nicht klären. Vermutlich liegen Spezies-
spezifische strukturelle Unterschiede der 5-HT2A-Rezeptoren vor. 
Basierend auf dem aktuellen Wissen und auf unseren Experimenten kann man 
schlussfolgern, dass die menschliche Thrombozytenfunktion durch endogenes 5-HT 
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nicht beeinflüsst wird, aber Thrombozyten sind wichtig, um das 5-HT im Blut zu 
erkrankten Organen und Geweben zu transportieren. Die Abwesenheit einer 
stimulierenden Wirkung von endogenem 5-HT auf Thrombozyten schliesst die 
Verwendung von 5-HT2A Rezeptor-Antagonisten als antithrombotische 
Medikamente jedoch aus. 
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10. Abbreviations and units 
 
10.1 Abbreviations 
5-HIAA 5-hydroxyindoleacetic acid 
5-HT 5-hydroxytryptamine, serotonin 
AA arachidonic acid 
ADP adenosine diphosphate 
AMP adenosine monophosphate 
ASA acetylsalicylic acid 
ATP adenosine triphosphate 
AU arbitrary units 
cAMP cyclic adenosine monophosphate 
CCD camera charge coupled device camera 
CD40-ligand cluster of differentiation 40-ligand 
CNS central nervous system 
COAT-platelet collagen-and-thrombin platelets or coated-platelets 
DAG Diacylglycerol 
Epi Epinephrine 
F-actin filamentous-actin 
G-actin globular-actin 
GPIbα glycoprotein Ibα 
GPCR guanosine nucleotide-binding protein coupled receptors 
G-protein guanosine nucleotide-binding protein 
GPVI glycoprotein VI 
IL-1 interleukin 1  
IP3 inositol trisphosphate 
LPA lysophosphatic acid 
LTA light transmittance aggregometry 
MAO Monoaminooxidase 
MEA multiple electrode aggregometry 
MI myocardial infarct 
OCS open canalicular system 
[105] 
 
PAI-1 plasminogen activator inhibitor-1 
PAR-1 proteinase-activated receptor 1 
PAR-4 proteinase-activated receptor 4 
PDGF platelet-derived growth factor 
PF-4 platelet factor 4 
PKC protein kinase C 
PLC phospholipase C 
PPP platelet poor plasma 
PRP platelet rich plasma 
SERT serotonin transporter 
SNARE soluble NSF attachment protein receptor 
SSRI selective serotonin re-uptake inhibitors 
TPH tryptophan hydroxylase 
TRAP thrombin receptor activating peptide 
TxA2 thromboxane A2 
VEGF vascular endothelial growth factor 
VSMC vascular smooth muscle constriction 
vWf von Willebrand factor 
β-TG beta-thromboglobulin 
 
10.2 Units 
g gram 
L liter 
M molar (=mol/liter) 
µg microgram 
µl microliter 
μM micromolar 
mg miligram 
ml mililiter 
mm milimeter 
mM milimolar 
min minute 
ng  nanogram 
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nM nanomolar (=nmol/l) 
nm nanometer 
rpm revolutions per minute 
s, sec second 
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11. Eidesstattliche Versicherung  
 
 
 
